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The purpose of this research project was to investigate the physicochemical 
and drug release properties of polymeric drug delivery systems prepared by hot-melt 
extrusion containing either highly water-soluble drugs or a poorly water-soluble drug.  
The properties of processed materials were characterized by thermogravimetric 
analysis (TGA), differential scanning calorimetry (DSC), stability indicating RP-
HPLC assay, dissolution studies, scanning electron microscopy (SEM), X-ray 
diffractometry, electronic torque rheometry, Zeta potential particle size analysis, and 
helium pycnometry. 
Chlorpheniramine maleate (CPM), diltiazem hydrochloride (DTZ), 
indomethacin (IDM), and the excipients were thermally and chemically stable 
following hot-melt extrusion.  CPM decreased the glass transition temperature (Tg) of 
 vii
Eudragit RS PO and exhibited a solid-state plasticization effect. CPM and IDM were 
in the amorphous state and DTZ was in the crystalline state following hot-melt 
extrusion processing.  Triethyl citrate (TEC) facilitated the hot-melt extrusion process 
by decreasing the Tg and the melt viscosity of Eudragit RS PO.  However, the 
thermal lubricant, glyceryl monostearate (GMS), only decreased the melt viscosity of 
the Eudragit RS PO.  The CPM release rate constant decreased in the order from 
tablets prepared by direct compression, hot-melt granulation, and hot-melt extrusion. 
This was due to an increase in the intermolecular binding and entanglement between 
drug molecules and polymer molecules that occurred during thermal processing. Post-
processing thermal treatment of the hot-melt extrudates had a minimal effect on 
decreasing the drug release rate since the hot-melt extrusion process enhanced the 
entanglement of the drug and polymer to a greater extent.  Drug release rates from 
both DTZ and CPM hot-melt extrudates increased with an increase in the TEC level 
in the formulations, while DTZ release from the Eudragit RS 30D coated pellets 
decreased with an increase of TEC in the coating layer. This could be attributed to the 
fact that a continuous polymeric structure was formed following hot-melt extrusion 
regardless of the TEC level. However, for the film coated pellets, coalescence of the 
polymer particles was enhanced with higher levels of TEC. Due to the lower 
solubility of IDM, no significant difference in drug release was observed in the IDM 
hot-melt extrudated granules containing 0%, 4%, and 8% TEC.  
 viii
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CHAPTER ONE: INTRODUCTION 
 
1.1. Polymeric Controlled Drug Delivery Systems Prepared by Hot-
melt Extrusion 
 
1.1.1. Significance of polymeric controlled drug delivery systems 
Polymeric controlled drug delivery systems offer numerous advantages when 
compared with conventional dosage forms, including improved efficacy, reduced 
toxicity, and improved patient compliance (1, 2).  
Controlled drug delivery technology represents one of the frontier areas of 
science, and the design and development of novel therapeutic systems involves a 
multidisciplinary scientific approach.  
From a manufacturing point of view, oral polymeric drug delivery systems 
can be developed and designed by several processing methods. By modifying 
polymer properties, a matrix system may be fabricated for sustained or controlled 
drug delivery. Pharmaceutical polymeric materials with little or no toxicity serve as 
membranes or matrices in which the active ingredient is dispersed or dissolved. 
Polymers also function as carriers, and may be attached to the active ingredient. 
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These carriers can be used to deliver a wide variety of drugs at a controlled rate in the 
gastrointestinal tract.  
 
1.1.2. Advantages of hot-melt extrusion 
Hot-melt extrusion is one of the most widely applied processing techniques in 
the plastics industry. Film, tubing, pipes, insulation, and home siding are produced 
with this thermal processing. In each case, the size and shape of the extrudate is 
determined by the die geometry, and solidification is determined by cooling the 
processed material. For pharmaceutical systems, several research groups have 
recently demonstrated that thermal processing of pharmaceutical powders is a viable 
method to prepare granules, sustained release tablets and transdermal drug delivery 
systems.  
For pharmaceutical applications, hot-melt extrusion offers many advantages 
over traditional processing techniques (3). Because hot-melt extrusion is a solvent-
free process, there are no concerns with solvent handling or recovery after processing. 
Solvents are not needed for processing, therefore fewer processing steps are necessary 
and time-consuming drying steps are eliminated. Also, there are no requirements on 
the compressibility of the active ingredients. The intense mixing and agitation by the 
extruder screw during processing causes suspended drug particles to deaggregate in 
the polymer melt, resulting in a uniform dispersion of fine particles.  Drug 
bioavailability may therefore be improved by dispersion of the drug substance at the 
molecular level in hot-melt extruded dosage forms. In addition, there is the possibility 
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of including a high dose of freely soluble drug in the extrudates without them losing 
their sustained release properties. This is sometimes difficult to achieve with other 
processing methods. The entire procedure is simple, continuous, efficient, and readily 
scaled-up. 
 
1.1.3. Hot-melt extrusion process 
Hot-melt extrusion equipment consists of an extruder, downstream auxiliary 
equipment and other monitoring tools used for performance and product quality 
evaluation. The extruder is typically composed of a feeding hopper, barrel, screw, die, 
screw driving unit and a heating/cooling device. The heart of the extruder is an 
Archimedean screw rotating inside a barrel. It is capable of pumping materials under 
a set of operating conditions at a specific rate. 
During the hot-melt extrusion process, a blend of the active ingredients, the 
thermoplastic polymers and other processing aids is fed into the barrel of the extruder 
through the hopper. The materials are transferred inside the heated barrel by a rotating 
screw.  Temperatures at different zones are controlled by several thermocouples in 
the barrel. The materials melt at elevated temperatures and the molten mass is 
continuously pumped through the die attached at the end of the barrel. Materials are 
subject to only a few minutes in the extruder (4). Depending upon the dimensions of 
the die cylinders, films can also be produced from the extruder. 
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1.1.4. Mechanism of hot-melt extrudate formation 
Unlike the case of a polymer dissolved in solvent, not all of the lattice sites are 
occupied by a molten polymer. Some may be vacant, though as in the case of a 
solution, the remainder can be occupied by no more than one segment of the polymer 
chains. During molecular motion in a polymer melt, the vacant sites or holes can be 
envisaged as jumping about and effectively swapping sites with individual polymer 
segments. When a stress is applied to the bulk polymer melt, the mass flows in the 
direction that relieves the stress. At the molecular level, the probability of a molecular 
jump becomes higher in the direction of the stress than in any other direction and 
hence these stress-relieving motions predominate, leading to the observed pattern of 
flow. Viscous flow takes place by successive jumps of such segments until the entire 
macromolecule has shifted. The overall result is that in the melt the polymer 
molecules adopt following Gaussian configurations and behave as thermo-
dynamically ideal entities (5). 
From a molecular point of view, the process of hot-melt extrusion involves the 
high temperature transformation of a solid mass of intertwined molecules into a 
viscous liquid or semi-solid mass. The resulting mass emerges from the die as the 
result of a compelling force.  
In hot-melt extruded drug delivery systems, the active compound is embedded 
in a carrier formulation comprised of one or more meltable substances and other 
functional excipients. The energy required to melt polymers in single-screw 
plasticating extruders is derived primarily from viscous dissipation and to a lesser 
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extent from heat transfer through the barrel wall. The melting-rate is highly 
dependent upon the physical and rheological properties of the polymer. It rises with 
increasing values of melt density, thermal conductivity, and melt viscosity, but 
decreases with increasing specific heat or heat of fusion. More viscous materials and 
amorphous materials melt faster (6). 
 
1.1.5. Solid dispersions for controlled release 
1.1.5.1. Solid dispersion technology 
Solid dispersion technology is the science of dispersing one or more active 
ingredients in an inert matrix in the solid state in order to achieve altered solid-state 
properties, such as increased solubility and dissolution rate, sustained drug release, 
and improved stability (7). 
There are many factors influencing the bioavailability of a pharmaceutical 
product. The two most important physicochemical properties of a drug are its 
solubility and permeability. As a general rule, if a drug substance has an aqueous 
solubility of less than 10mg/ml, dissolution is the rate-limiting step in the process of 
drug absorption (8). Formulation of poorly water-soluble drugs for oral delivery 
presents one of the most frequent and greatest challenges to pharmaceutical scientists.  
The Noyes-Whitney equation describes the factors influencing drug release:  
dC/dT = AD(Cs-C)/h       ( 1 ) 
where dC/dT is the rate of dissolution, A is the surface area available for 
dissolution, D is the diffusion coefficient of the drug, Cs is the solubility of the drug 
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in the dissolution medium, C is the concentration of drug in the medium at time t and 
h is the thickness of the diffusion boundary layer adjacent to the surface of the 
dissolving drug. 
According to this equation, the main possibilities for improving dissolution 
rate are to increase the surface area by decreasing the particle size of the solid drug; to 
increase the drug diffusion coefficient by selecting a suitable carrier; to increase its 
solubility by changing its physical and/or chemical structure; to ensure sink 
conditions by minimizing the drug concentration in the medium; and lastly to 
decrease the boundary layer thickness by optimizing the wetting characteristics of the 
drug surface.  
Through application of the Noyes-Whitney equation, it can be determined that 
maximizing the rate of dissolution occurs by the following physical and chemical 
modifications. 
Decreasing the particle size of the compound by milling the drug theoretically 
results in an increase in the available surface area for dissolution. However, in some 
cases the micronized powder tends to agglomerate, and may consequently become a 
disadvantage of the milling process. Surfactants are often incorporated into a 
formulation to increase drug solubility due to their amphiphilic functions. At higher 
concentrations, surfactant micelles will be formed and this will also enhance drug 
solubility. Some drugs may exist in more than one crystalline form due to different 
molecular arrangements. Polymorphs generally have different solubilities, melting 
points, and x-ray diffraction patterns, even through they are chemically identical. 
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Crystalline molecules of a drug form a compact crystal with high lattice energy and 
consequently low solubility. However, amorphous drugs have high solubility. 
Complexation is another method to improve drug dissolution and works via the 
inclusion of poorly water-soluble drugs into β-cyclodextrin. The research in this area 
thus far has been very promising. Chemical modifications can be utilized to increase 
dissolution rates. This includes making a soluble salt or a prodrug.   
 
Methods for preparing solid dispersions 
Hot melt method 
Sekiguchi and Obi used a hot melt method to prepare simple eutectic 
mixtures. Sulfathiazole and urea were melted together at a temperature above the 
eutectic point, which is the lowest possible melting temperature of the mixture, and 
then cooled in an ice bath.  The resultant solid eutectic was then milled to reduce the 
particle size (9).  
The advantage of the hot-melt method is that it does not require finding a 
mutual solvent for both the drug and the polymeric carrier. For example, this hot-melt 
method was used to prepare probucol and polyethylene oxide (PEO) solid dispersions 
(10), since no mutual solvent could be found for these two components. 
An important prerequisite for the manufacture of solid solutions by the hot 
melt method is the miscibility of the drug and the carrier in the molten state. When 
there are miscibility problems, this usually leads to a product that is not molecularly 
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dispersed. This problem can be solved by selecting a suitable carrier that shares 
similar physicochemical properties with the drug. 
Another limitation to the hot melt method is the thermostability of the drug 
and the carrier. If too high a temperature is required, the drug may decompose or 
evaporate. In recent years, the hot melt method has enjoyed recognition in the form of 
hot melt extrusion. An important advantage of the hot melt extrusion method is that 
the drug/carrier mixture is only subjected to elevated temperatures for a few minutes, 
which enables both the drug and the carrier to remain thermally stable. 
 
Solvent evaporation method 
The solvent evaporation method may provide another way to solve the 
thermal stability problem associated with the preparation of solid dispersions.  
In the solvent evaporation method, solid dispersions were prepared by 
dissolving both the drug and the carrier in a common solvent and then evaporating the 
solvent under a vacuum.  
An important prerequisite for the manufacture of a solid dispersion using the 
solvent evaporation method is that both the drug and the carrier are sufficiently 
soluble in the solvent. The solvent can be removed by any one of a number of 
methods such as freeze-drying or spray-drying. When an organic solvent is to be 
removed, small variations in the conditions used can lead to quite large changes in 
product performance. Another point to be considered is the importance of thoroughly 
removing all of the solvent, since most organic solvents used have toxicity issues. 
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With the discovery of the solvent evaporation method, many problems 
associated with the melt method were solved. For example, it was then possible to 
form solid dispersions from thermoliabile substances. Previously many polymers 
could not be utilized for the melt method due to their high glass transition temperature 
(e.g. PVP K25 has a Tg of 155°C). PVP could be considered as a carrier for solvent 
evaporation method. As a result, for many years the solvent evaporation method was 
the method of choice for many polymer-based systems. With time, however, the 
ecological and subsequent economic problems associated with the use of organic 
solvents began to make solvent-based methods more and more problematic. For these 




Polyethylene glycol (PEG) 
PEG is one of the most frequently used materials for the preparation of solid 
dispersions for three reasons. Good water solubility makes it capable of producing a 
fast drug release. Good solubility in many organic solvents makes it easier to be 
prepared by the solvent evaporation method. Also lower melting points, under 65°C, 
make it easier to be processed by the melt method.  
However, there are a few problems with the application of PEG. For example, 
there are stability problems encountered during preparation by the hot-melt method. If 
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the dispersion is too soft it can be difficult to conduct the subsequent formulation. 
This is most likely to occur if a low MW PEG is used or if a drug has a plasticizing 
effect on the PEG. 
 
Polyvinylpyrrolidone (PVP) 
In general, the glass transition temperature of the amorphous polymer PVP is 
high (Tg of PVP K30 is 163°C (10) ). For this reason PVP has only limited 
application for the preparation of solid dispersions by the hot-melt method. Due to its 
good solubility in a wide variety of organic solvents, it is particularly suitable for the 
preparation of solid dispersions by the solvent evaporation method.  
Most studies of PVP solid dispersions reported in the literature have used PVP 
of MW of 2,500-50,000. Beyond 50,000 the aqueous solubility of PVP decreases and 




The glass transition temperatures of most polysacchrides are relatively high. 
This makes the preparation by hot melt method problematic. Also, their solubility in 
most solvents is poor. This makes it difficult to prepare coevaporates. Despite these 
drawbacks, several attempts to prepare solid dispersions using polysacchrides have 
been reported by other researcheres. 
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Characterization of solid dispersions 
Whether or not a solid dispersion has achieved an improved dissolution rate 
can be investigated using the dissolution test. Thermal analysis methods such as 
thermal gravimetry analysis (TGA) and differential scanning calorimetry (DSC) can 
be used to investigate the thermal stability and glass transition temperature of the 
materials used. Lack of a melting peak in the DSC of a solid dispersion indicates that 
the drug is present in an amorphous form rather than a crystal form. This result can 
also be confirmed by the X-ray pattern. It is usually assumed that dispersions in 
which no crystallinity can be detected are molecularly dispersed. The absence of 
crystallinity is used as a criterion to differentiate between solid solutions and solid 
dispersions. Infrared spectroscopy (IR) is used to investigate the drug and polymer 
interaction. Scanning electron microscopy is another method employed to distinguish 
between a solid solution and a solid dispersion. 
 
Applications of solid dispersion to enhance dissolution 
Since the first report on the solid dispersion technology, several authors have 
published some excellent reviews on this topic (11-13). 
The first report on the concept and advantages of solid dispersion 
formulations was published by Sekiguchi and Obi in 1961 (9). They demonstrated 
that a eutectic mixture of sulfathiazole and urea had a much higher dissolution rate, 
leading to better absorption following oral administration, as compared to 
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sulfathiazole administered alone. The explanation offered for this behavior was that 
when a mixture consisting of a poorly water-soluble drug and an inert, highly water-
soluble carrier, is dissolved in an aqueous medium, the carrier will dissolve rapidly, 
releasing very fine crystals of the drug. The large surface area of the resulting 
suspension should result in an enhanced dissolution rate and thereby improved 
bioavailability.  
In the case of a solid solution, a further reason for the improvement in the 
dissolution rate is that the drug is in an amorphous form rather than a crystalline 
structure in the solid solution.  
Solid dispersions were prepared with a non-steroidal anti-inflammatory and 
slightly water-soluble drug, flurbiprofen (the solubility is about 30mg/ml of water at 
37°C), and water-soluble polymers, hydroxypropylcellulose (HPC) or poly(ethylene 
oxide) (PEO), by the solvent (ethanol) method. The release rate of flurbiprofen from 
the flurbiprofen-PEO system was significantly larger than that from flurbiprofen 
powder and the flurbiprofen-HPC system. The dissolution property of the polymer 
greatly affected the release of flurbiprofen from the solid dispersions. In the 
flurbiprofen-PEO system, the release rate increased with the increasing percentage of 
PEO (14). 
Solid dispersions of itraconazole prepared with pH-dependent hydrophilic 
polymers, polyvinylacetal diethylaminoacetate and Eudragit® E 100, by a spray 
drying method resulted in greater increases in drug solubility over those prepared 
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with pH-independent hydrophilic polymers, PEG 20,000, PVP, Poloxamer® 188 and 
HPMC. Tablets containing the solid dispersion particles prepared by spray drying 
showed enhanced dissolution profiles of itraconazole over the marketed product (15). 
Binary solid dispersions containing a poorly water-soluble drug, atenolol and 
different polymers, including povidone (PVP), crospovidone (PVP-CL), 
polyvinilpyrrolidone/vinylacetate (PVP/VA), and Eudragit® E were prepared by the 
solvent (methanol) evaporation method. The drug was always present in a crystalline 
form in the PVP-CL and Eudragit® E systems, while with the high content of PVP 
and PVP/VA an amorphous atenolol was detectable. An improvement in solubility 
and dissolution rate of atenolol with PVP and PVP-CL was obtained (16).  
Phospholipid coprecipitates containing indomethacin were prepared by the 
solvent method and were shown to have good industrial potential to increase the 
dissolution of poorly water-soluble drugs. The mechanism of improved dissolution 
was due to the conversion of the crystal structure of indomethacin into an amorphous 
form and continuous erosion of the drug from the matrix of the phospholipid (17). 
Up to 50% of indomethacin can be dispersed in an amorphous state in 
Eudragit® E-100.  Because of the good solubility of Eudragit® E-100 at pH 1.2, a fast 
dissolution rate of drug was observed while a marked delay was noticed at pH 7.5 
where the polymer is only permeable to water. At pH 5.8 the kinetics of drug release 




The main concerns with solid dispersions have been the ability to scale-up the 
manufacturing method and the physical stability of the dispersion. The application of 
hot melt extrusion to the production of solid dispersions is a particularly important 
breakthrough for the scale-up of solid dispersion manufacture. Also, researchers have 
shown that PVP can inhibit the recrystallization of indomethacin from the 
supersaturated solid solution when the storage temperature is 40-50°C below the Tg 
of indomethacin (19). Experience with solid dispersions over the last 40 years 
indicates that this is a very promising approach to improving the release rate and oral 
bioavailability of poorly water-soluble drugs.  
 
1.1.5.2. Solid dispersions containing water-soluble drugs for controlled release 
Solid dispersion technology is commonly used to enhance the dissolution 
properties of poorly water-soluble drugs by the incorporation of water-soluble 
materials. By dispersing a given drug into an inert carrier the drug dissolution can 
either be accelerated or retarded depending upon the solubility or permeability of the 
carrier. Recently several water insoluble polymers were used to prepare solid 
dispersions containing freely water-soluble drugs for controlled release purposes.  
Four sustained release solid dispersion dosage forms of pilocarpine 
hydrochloride (PC) with ethylcellulose and/or hydroxypropylmethylcellulose 
phthalate were prepared by the organic solvent method. One preparation was 
composed of PC : ethylcellulose :  hydroxypropylmethylcellulose phthalate at a 
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weight ratio of 1:9:10, and showed the best sustained release behavior in dissolution 
testing among the four preparations. This preparation was examined by powder X-ray 
diffractometry and differential scanning calorimetry, and was confirmed to be a solid 
dispersion (20). 
Solid dispersion films of lidocaine hydrochloride (LDC), a highly water-
soluble regional anesthetic agent, were prepared with a water-insoluble ethylcellulose 
(EC) and water-soluble hydroxypropylcellulose (HPC) using the solvent (ethanol) 
evaporation method. The controlled release profiles of LDC from the solid dispersion 
films of different compositions were achieved at the EC/HPC composition ratio of 
5/5. The mechanism of controlled release was speculated to be that there was little 
release of HPC together with LDC, and the retained HPC swelled in the film by the 
permeating fluid. Then, the release of LDC occurred via diffusion into the swelled 
HPC phase, causing a marked decrease in the release rate. LDC exists as an 
amorphous form in the solid dispersion films containing HPC. The film for clinical 
use, which had the 30% LDC solid dispersion film, adhered almost completely to the 
buccal mucosa. These observations will provide useful information on clinical 
application of the LDC-EC-HPC solid dispersion film (21). 
Solid dispersions containing three levels of ethylcellulose and acetaminophen 
(1:3; 1:1; 3:1) were prepared by the solvent evaporation method to achieve prolonged 
drug release. Systems composed of solid dispersions or physical mixtures containing 
the equivalent weight of 50 mg acetaminophen, Emcompress as diluent and 1% 
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magnesium stearate as lubricant were compressed into tablets. The dissolution data 
showed that the drug release decreased as the level of ethylcellulose increased in the 
solid dispersion formulations. The drug release from tablets prepared with solid 
dispersions followed the diffusion controlled model for an inert porous matrix, while 
the drug release from tablets prepared with physical mixtures followed the first-order 
kinetic model (22). 
 
1.1.5.3. Solid dispersions containing poorly water-soluble drugs for controlled 
release 
In addition to bioavailability enhancement for poorly water-soluble drugs, 
solid dispersion technology has also been employed to prepare the sustained release 
dosage forms for these drugs.  
Misoprostol is difficult to formulate due to its instability and viscous liquid 
form. A stable sustained release solid dispersion of misoprostol with Eudragit 
RS/RL was prepared. The solid dispersion matrix formed can protect misoprostol 
from being degraded by water so that the stability of misoprostol is improved. In 
addition, misoprostol can be slowly released by diffusion from the copolymer matrix 
(23).  
Phenacetin (PHE, water solubility is 1.31mg/ml at 37°C) solid dispersions 
were prepared with polyethylene oxide (PEO) and different grades of Carbopol (CP) 
in the mixture of water-ethanol by the solvent evaporation method (50°C, 24 hours). 
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The release rate of PHE from the PHE-PEO system was larger than that from PHE 
powder. In the PHE-CP system, almost the same release rate was observed as PHE 
powder. The release rate from the PHE-PEO-CP system varied depending on the 
PEO/CP ratio and reached the minimum level at the PEO/CP ratio of 1/1 (w/w) (24). 
The release profile of PHE varied depending on the molecular weight of PEO. The 
minimum release rate was observed at the PEO molecular weight of 35,000. It was 
found that the amount of the PEO-CP complex formed by hydrogen bonding changed 
depending on the molecular weight of PEO (25). In another research study, they 
found that phenacetin existed in the amorphous state and the release of the drug was 
controlled by the ratio of polyethylene oxide and Carbopol as well as the Carbopol 
grade (26).  
A nifedipine (NF) polyethylene glycol (PEG) solid dispersion was prepared 
by the melting method. Three-layer hydroxypropylmethylcellulose (HPMC) matrix 
tablets were prepared containing this solid dispersion. Both the high-viscosity grade 
HPMC (Methocel K15M) and low-viscosity grade HPMC (Methocel K100) were 
applied in the tablets to form the matrix. The dissolution and absorption of NF from 
the tablet were evaluated and the formulation had a sustained release over 24 hours 
(27). 
In order to control the release rate of a slightly water-soluble drug, 
flurbiprofen, solid dispersions were prepared with a water-soluble polymer, 
hydroxypropyl cellulose by the solvent (ethanol) evaporation method. The release 
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rate of flurbiprofen from the solid dispersion granules was markedly larger than that 
from the flurbiprofen powder, and it was larger with a lower HPC molecular weight. 
X-ray diffraction study shows that flurbiprofen existed in the amorphous state in the 
solid dispersion (28). 
Furosemide is a diuretic and antihypertensive drug, and is practically 
insoluble in water. In order to achieve a controlled release characteristics for this 
drug, Aceves and coworkers prepared furosemide solid dispersions containing 
Eudragit RS/RL using the solvent (methanol) evaporation method (29). The X-ray 
diffraction profiles showed a transition from the crystalline to the amorphous phase 
for the prepared solid dispersions. Electronic microscopy analysis showed that the 
furosemide changed its crystalline habit from needle to a new spherical phase with a 
diameter around 1µ. Scanning electron microscopy showed the presence of 
microspheres within the polymeric matrix, and the channels formed due to the 
furosemide dissolution inside the Eudragit RS/RL, thus modifying the release 
pattern of the furosemide system.  
The poor and variable oral bioavailability of furosemide is due to the presence 
of a biological window in the upper gastrointestinal tract and the incomplete release 
of the drug from the units is related to its low water solubility. A multiple-unit 
floating system containing a 1:5 furosemide/polyvinylpyrrolidone solid dispersion 
was prepared by the solvent (methanol) evaporation method. The complete dose 
release over the actual gastric residence time of the system (about 8 hr) was achieved. 
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Physicochemical analyses suggested the predominant role of the amorphous state of 
furosemide is in producing enhanced drug solubility and dissolution rate, which led to 
the desired release profile from the floating units (30). 
The dissolution behaviour of controlled release solid dispersions of 
indomethacin containing Eudragit RS from different combinations of the drug in a 
solid dispersion form was investigated. Eudragit RS had a retardation effect on the 
release of indomethacin depending upon the amount of Eudragit RS included. 
Inclusion of sodium lauryl sulphate (SLS) in the solid dispersion modified the release. 
The kinetics of the release process was found to be best described by the Higuchi 
square root of time equation and the first order equation indicating that the release is a 
diffusion controlled process (31).  
Indomethacin and Eudragit RS coprecipitates and solid dispersions were 
prepared by dissolving the drug and polymers in alcohol and then precipitated using 
distilled water or evaporating the solvent. The IR data did not indicate a significant 
drug-polymer interaction. X-ray diffraction showed a reduction in crystallinity for the 
coprecipitates and solid dispersions. DSC revealed the conversion of indomethacin 
from Form I to Form II in solid dispersions and coprecipitates (32). The stability of 
these coprecipitates and solid dispersions was investigated by Khan et al (33). There 
was no significant change in the dissolution rates for samples stored at 4°C for 6 
months. This is because the rotational motion of indomethacin at 4°C may be reduced 
enough to inhibit crystallization. 
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1.2. Additives for Hot-melt Extrusion 
 
1.2.1. General requirements for additives used for hot-melt extrusion 
In general, all additives in the hot-melt extrusion formulation should have the 
following features: (1). Pharmaceutical grade for safety reasons. (2). Efficient in their 
functions without adversely affecting the functions of the other additives. (3). Stable 
under the thermal processing conditions. (4). Stable during the storage of the dosage 
form. Migration of the additives within the drug delivery system should be avoided to 
maintain the performance of the dosage form.  
 
1.2.2. Polymers  
Many pharmaceutical grade polymers have been used in controlled drug 
delivery systems due to their different permeabilities (34). The most common 
materials include hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), 
polyvinylpyrrolidone (PVP), and polyacrylic esters. These materials can be used as 
both matrix and coating materials to control drug release.  
To produce the pharmaceutical dosage forms via hot-melt extrusion, a 
pharmaceutical grade polymer must be selected that can be processed at a relatively 
low temperature due to the thermal sensitivity of most drugs. The molten or soft 
polymer melt can function as “thermal binders and/or drug release retardants” once 
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the material exits the extruder and solidifies. The choice of the polymer is also based 
on its processability and thermal stability. 
HPMC, EC, and PVP have higher glass transition temperatures, which limit 
their use in hot-melt extrusion processing to make solid dispersions. The acrylic 
polymers are amorphous and have relatively low glass transition temperatures (Tg) 
contributing to their thermal processability. The mechanical and thermal properties of 
polymers are dependent on the intermolecular attraction, the spatial symmetry and the 
stiffness of the side chain groups. As the side chain length of the acrylic polymer 
increases, the polymer molecules become spaced apart and intermolecular attraction 
is reduced, thus decreasing the softening point of the material.  However, polyacrylic 
materials having side chains consisting of 12 or more carbon atoms are brittle with 
high glass transition temperatures corresponding to the increased side chain length.  
Eudragit RS and Eudragit RL are acrylic and methacrylic acid esters. The 
structure of Eudragit RS and Eudragit RL differs only in the amount of the 
quaternary ammonium substitution, with RS being much lower than RL. Their 
permeability to water is unaffected by pH, but water can permeate more freely into 
Eudragit RL than RS, due to the presence of the ionized quaternary ammonium 
groups in the polymer.  
Polyethylene (processing temperature: 105~120°C), polycaprolactone 
(processing temperature: 60~70°C), polyvinyl acetate (processing temperature: 
170°C), and cellulose acetate butyrate (processing temperature: 195°C) were used in 
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a melt extrusion process to prepare matrix drug delivery systems containing 
theophylline (35). 
Poly(vinyl acetate) was used as a retardant polymer to control the drug release 
of theophylline from matrix tablets prepared by hot-melt extrusion. Poly(vinyl 
acetate) is  an amorphous polymer with a glass transition temperature of 32.7°C (MW 
12,000) and 35.9°C (MW 45,000) (36). Due to the low glass transition temperature of 
Poly(vinyl acetate), the hot-melt extrusion processing temperature was approximately 
70°C. 
Polyacrylic acid (PAA), an amorphous polymer, was found to have a Tg of 
132°C (10). Polyethylene oxide (PEO) is a semi-crystalline thermal plastic polymer 
and the crystalline regions melt at an onset temperature of 62°C. The Tg of the 
amorphous region of PEO is around –60°C (10). Depending on the molecular weight, 
the melting point of PEO ranges from 60°C to 75°C (37). These polymers can also be 
used in the hot-melt extrusion formulation. 
 
1.2.2. Plasticizers 
The use of polymeric carriers usually requires the incorporation of a 
plasticizer into the formulation in order to improve processing conditions during the 
manufacturing of the extruded dosage form or to improve the stability and 
physicochemical properties of the final product. 
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A plasticizer is a substance or material incorporated in a material (usually a 
plastic or elastomer) to increase its flexibility, workability, or distensibility. In 
addition, a plasticizer may reduce the melt viscosity, lower the temperature of a 
second-order transition, or lower the elastic modulus of the product (38). When a 
plasticizer is incorporated into a polymer, less energy is required for molecular bond 
rotation, and therefore polymers become capable of flow at temperatures below their 
decomposition temperatures.  
 
1.2.2.1.  Plasticization mechanisms 
Several plasticization mechanisms have been proposed. Briefly, they involve 
the lubricity theory, the gel theory, the free volume theory and the polar theory (38, 
39). 
In the lubricity theory, a plasticizer acts as a lubricant to facilitate movement 
of polymer macromolecules over each other. This reduction in intermolecular or van 
der Waals forces along the polymer chains gives internal lubricity and makes the 
polymer more flexible. 
The gel theory considers the plasticized polymer to be neither solid nor liquid 
but an intermediate state loosely held together by a three-dimensional network of 
weak secondary bonding forces. These bonding forces acting between plasticizer and 
polymer are easily overcome by applied external stresses allowing the plasticized 
polymer to flex, elongate, or compress. 
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The free volume of an amorphous material is the volume not occupied by the 
molecules making up the material (40). In the free volume theory, the motion of the 
main chain, chain ends, and side chains bring free volume for that polymer.  When 
plasticizer molecules insert themselves between polymer molecules, they reduce, but 
do not eliminate polymer-polymer contacts, thus generating additional free volume. 
According to the polarity theory, the intermolecular forces between the 
plasticizer molecules, the polymer molecules and the polymer/plasticizer molecules 
must be well balanced to ensure that the gel is stable. Therefore, plasticizers contain 
one or more of both polar and nonpolar groups which must match the polarity of the 
polymer. The polarity of a plasticizer molecule depends on the presence of groups 
containing oxygen, phophorus and sulfur. In terms of chemical structure, a plasticizer 
is a polar aromatic compound comprised of polar, polarizable and nonpolar portions.  
 
1.2.2.2.  Effects of plastcizers 
Plasticization exhibits several effects on a polymeric pharmaceutical product: 
1) facilitates thermal processing; 2) modifies drug release from the polymeric system; 
3) influences mechanical properties of the polymeric system; and 4). enhances the 
appearance of the dosage form. 
Vitamin E TPGS (TPGS, - -tocopheryl polyethylene glycol 1000 
succinate) has been utilized for numerous applications in pharmaceutical dosage 
forms. Its chemical structure contains both a polar and a non-polar moiety making it 
similar to a conventional surface-active agent. The chemical properties of this 
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distinctive compound have suggested its use as a solubilizer, an emulsifier, an 
absorption enhancer, and a water-soluble source of vitamin E (41). This material can 
decrease the glass transition temperature of the mixture of HPC and PEO and acted as 
a plasticizer. Repka and McGinity found that the addition of Vitamin E TPGS in a 
mixture of HPC and PEO decreased both the pre-die pressure and the torque of the 
hot-melt extrusion process, suggesting that this plasticizer facilitated the thermal 
processing (42). 
Polyethylene glycol can function as a plasticizer to improve the stability of the 
polymer for hot-melt extrusion processing. It was reported that when 40% of PEG 
3350 was included there was no significant difference in the weight average 
molecular weight of PEO following the processing. Without the addition of PEG, a 
15% decrease in the molecular weight of PEO was detected (37).  
The influence of a plasticizer in Eudragit RS 30D coating layer on drug 
release was investigated by Bodmeier et al. Propranolol hydrochloride beads were 
coated with Eudragit RS 30D containing TEC. A U-shape drug release was found. 
The release rate constant was high at low plasticizer levels, then went through a 
minimum plateau, and increased at higher plasticizer concentrations. The U-shaped 
curve could be explained that at low plasticizer levels, the latex particles were 
insufficiently plasticized. This interfered with the coalescence or fusion of the latex 
particles and resulted in the faster release. At high levels of TEC, the increase in 
release rate constant could be explained with the leaching out of the TEC (43). 
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Mehta et al prepared a multi-unit controlled release system of a poorly water-
soluble thiazole based leukotriene D4 antagonist containing Eudragit® L 100 55 and 
Eudragit® S 100 by an extrusion/spheronization technique (44). When 15% triethyl 
citrate, based on the Eudragit weight, was incorporated into the pellet formulation 
with 1:1 and 1:3 ratios of Eudragit L 100 55: Eudragit S 100 respectively, 
enhanced drug release from the pellets was observed compared with the 
corresponding pellets without the plasticizer. The authors attributed this result to the 
increased dissolution rate of the plasticized polymer. 
Wu and McGinity (45) investigated the influence of a non-traditional 
plasticizer, methylparaben, on the release of ibuprofen from beads coated with 
Eudragit RS 30D containing methylparaben. The drug release rate decreased when 
the methylparaben levels were increased from 5% to 15%. Wu and McGinity also 
investigated the influence of the non-traditional plasticizer, methylparaben, on the 
mechanical properties of Eudragit RS 30D coated beads. It was found that the higher 
levels of the methylparaben incorporated into the film resulted in a decrease in the 
tensile strength of the film. The decrease was attributed to an increase in the 
flexibility of the polymeric films when the level of methylparaben in the polymeric 
dispersion was increased. 
 
1.2.3. Thermal lubricant 
1.2.3.1. Thermal lubricant and lubrication mechanism 
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Thermal lubricants may be defined as materials which are added into the 
formulation to improve its procesability (46) in the hot-melt extrusion process. 
Thermal lubricants decrease the melt viscosity of the materials in the formulation and 
reduce the friction of molten materials in the extruder during thermal processing. 
When added in the formulation, thermal lubricants not only enhance thermal 
processing but also affect the dosage form performance. 
External lubricants form a thin film layer between the molten polymer and the 
metal surfaces of the processing equipment, which helps to prevent the composition 
from sticking to the machinery and thus facilitates thermal processing. Such materials 
have a low compatibility with the polymer and often possess polar groups to enhance 
their affinity to metals. These materials will normally be a fluid at processing 
temperatures, and should have a solubility parameter at least 3Mpa1/2 different from 
the polymer. 
The internal lubricants comprise low molecular weight materials which 
promote the flow of the polymer in the melt, but unlike plasticizers they have little 
effect on the solid state properties. Compatibility between the internal lubricant and 
polymer is therefore a requirement.  The internal lubricants will generally have 
similar solubility parameters to the base polymer, but are much less viscous at 




Oxidation may occur with some drugs and polymers under thermal processing 
conditions. To prevent thermal oxidation, antioxidants need to be incorporated into 
the formulation to improve stability. 
 
1.3. Characterization of Hot-melt Extruded Polymeric Drug Delivery 
Systems 
 
1.3.1. Drug release mechanisms 
1.3.1.1. Factors influencing drug release 
Permeability of the drug through a polymeric material is a three-part process 
involving dissolution, migration and diffusion of the drug molecules as a function of 
solubility and the diffusion coefficient.  
Temperature influences the drug release rate by changing the polymer 
microstructure. Below the glass transition temperature, there is a reduction in “free 
volume” and the polymer segments have little mobility. This means that not only are 
there less voids, but also a diffusing particle will have a more tortuous path to 
penetrate through the polymer.  
Crystalline structures of a polymer have a much greater degree of molecular 
packing. The individual lamellae can be considered as almost impermeable so that 
diffusion can occur only in amorphous zones of imperfection. Hence, crystalline 
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polymers will tend to resist diffusion more than either rubbery or glassy polymers 
with the same chemical structure. 
 
1.3.1.2. Mathematical models 
 Several mathematical models as seen in Table 1.3.1 have been proposed to 
investigate the drug release mechanism, including the Higuchi equation (47), zero 
order equation, first order equation (48), the Hixson-Crowell equation (49), the 
Korsmeyer-Peppas equation (50-52), and the Baker-Lonsdale equation (53). The 
Hixson-Crowell equation indicates an erosion-dependent release mechanism in which 
the release rate is controlled by the dissolution rate of the drug particles and the 
Higuchi equation describes a diffusion release mechanism. 
 Griffin proposed a dual equation combining first-order and square-root-of-
time release kinetics to fit the drug release profiles from various multiparticulate 
controlled release dosage forms containing a lipophilic coating layer. The statistical 
output from nonlinear regression software suggests that this equation describes the 
data better than the individual equations alone (54). 
 It was observed that the release profiles from the extrudates containing 
ditiazem hydrochloride and Eudragit® RS PM were biphasic with a rapid release of 
the drug easily accessible at the surface of the pellets and a slow second phase where 
diffusion prevails. A double exponential equation M = A0 (1-e-αt) + B0 (1-e-βt) was 
used by N. Follonier et al (55).  
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1.3.1.3. Dissolution profile comparison 
The dissolution profile comparison may be carried out using a model 
independent method as suggested by the FDA by calculating the similarity factor f2 
value, which is a logarithmic reciprocal square root transformation of the sum of the 
squared differences in drug release percentage for the two delivery systems (56).  
 
where n is the number of time points, Rt is the release percentage of the reference 
batch at time t, and Tt is the release percentage of the test batch at time t. Two 
dissolution profiles are declared similar if f2 is greater than 50.  
 
1.3.2. Crystallinity 
1.3.2.1.  X-ray diffraction 
X-ray diffraction can be used to study the crystallinity of materials. In X-ray 
diffraction, the average degree of crystalline order is measured with a lower limit of 
detection around 10% (57). Some drugs may exist in more than one crystalline form 
and exhibit polymorphic characteristics. Polymorphs generally have different 
solubilities, melting points, and X-ray diffraction patterns, even though they are 
chemically identical.  Crystalline molecules of a drug form a compact crystal with 
high lattice energy and consequently low solubility.  However, amorphous drugs have 


































amorphous forms. This is the fundamental theory for using the hot-melt extrusion 
technique to improve the bioavailability of poorly-water soluble drugs. The absence 
of crystallinity is used as a criterion to differentiate between solid solutions and solid 
dispersions. Lack of a melting peak in the DSC of a solid dispersion indicates that the 
drug is present in an amorphous form rather than a crystalline form. The presence or 
absence of crystallinity can be confirmed by examining the X-ray pattern of the hot-
melt extrudate.  
 
1.3.2.2.  Raman spectroscopy 
FT-Raman spectroscopy provides molecular information about both the 
crystalline and the amorphous phases. It has recently been used to quantify mixtures 
of polymorphs, utilizing distinct spectral peaks characteristic of each form or factor 
analysis techniques. One advantage of FT-Raman spectroscopy is that no sample 
preparation is necessary, thus, the likelihood of inducing phase changes through 
processing is reduced. However, sample heating is a well-known problem associated 
with laser Raman spectroscopy, which could result in crystallization of the sample. 
Non-homogeneities in mixing are another source of error in quantitating the degree of 
crystallinity (58). 
Results from the DSC measurements should be interpreted with caution since 
changes in the physical state of solid dispersions may occur during heating, and the 
presence of the polymer may influence the melting behavior of the drug e.g. through 
melting point depression. Thus the Raman results are considered to be a more reliable 
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indicator of the solid-state modification of the drug present in the solid dispersions 
since they are obtained at room temperature and involve minimal sample handling. 
 
1.3.3. Microstructures 
Unique microstuctures are formed during hot-melt extrusion processing as a 
result of temperature and pressure on the material as it passes through the heating 
zones of the extruder. The microstructure of the extruded materials will influence the 
drug release properties of the delivery system. Scanning electron microscopy can be 
employed to investigate the microstructure and to distinguish between a solid solution 
and a solid dispersion.  
 
1.3.4. Drug and polymer interaction 
 Drug and excipient interaction influences the drug release mechanisms. The 
adsorption phenomenon is one example of the drug and excipient interaction. 
Physical adsorption is due to electrostatic interactions, hydrogen bonding or van der 
Waals forces and is usually reversible; while in chemical adsorption, the adsorbate is 
attached to the adsorbent by primarily chemical bonds, including ion exchange, 
protonation and complexation, and is irreversible (59). The extent of adsorption 
depends on the physicochemical properties of both the drug and the excipient. 
Eudragit® RS and Eudragit® RL are copolymers contain a low level of 
quaternary ammonium groups. The presence of both reversible and irreversible 
binding between salicylic acid and Eudragit® RL was reported, suggesting more than 
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one type of binding interaction (59). The reversibility of salicylic acid binding with a 
change in ionic conditions supported the theory that the drug interacted with these 
polymers primarily via ionic electrostatic interactions. Dissolution release profiles for 
both drugs were directly correlated to drug-polymer interactions. Decreases in pH or 
increases in ionic strength that minimized ionization of the drug resulted in decreased 
drug sorption and increased drug release from the films.  
Interactions between indomethacin and Eudragit® RL were found to follow a 
type I Langmuir equation (60) and it is too high to get a 100% drug release (61). For 
Eudragit® RS 100, due to its relatively lower amount of the quaternary ammonium 
groups than Eudragit® RL, it was reported that no strong interaction between 
indomethacin and Eudragit® RS 100 was observed from the IR spectra of 
indomethacin, indomethacin and Eudragit RS 100 physical mixture, corecipitates, as 
well as solid dispersions (62). 
In order to investigate the interaction between drugs and Eudragit® RL or 
Eudragit® RS resins under physiological conditions, molecular dynamics simulations 
were performed on systems containing water molecules, Eudragit® molecule 
fragments and furosemide, indomethacin, nicotinamide or etilefrine as model drug 
molecules. The interaction energies were monitored as well as the drug¯Eudragit® 
distances to quantify and visualize the amount of drug binding. The nature of the 
calculated intermolecular interactions was examined by separate evaluation of H-
bonding, ion¯ion (electrostatic) and hydrophobic (van der Waals) interaction energies. 
It could be shown that van der Waals, electrostatic and H-bond energies may lead to a 
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great portion of furosemide and indomethacin binding to Eudragit® RL rather than to 
Eudragit® RS. Nicotinamide and etilefrine showed no tendency to interact with the 
molecule fragments of the Eudragit® resins. The calculated results were verified by 
experimental determinations of the amount of drug binding to Eudragit® RL and 
Eudragit® RS in isotonic pH 7.2 buffer solution after an equilibration period of 24 h. 
The amounts of drug binding to Eudragit® RL were 93.1% for furosemide and 72.4% 
for indomethacin, whereas the amounts of drug binding to Eudragit® RS were 31.4% 
for furosemide and 26.5% for indomethacin. No drug binding to the Eudragit® resins 
was observed for nicotinamide and etilefrine. The experimentally obtained binding 
rates were in excellent agreement with the calculated binding energies. This may be 
interpreted as an indication for the correctness of the proposed intermolecular 
interaction mechanisms between the four model drugs and the Eudragit® resins in the 
presence of water (63).  
 For the adsorption-desorption effect of cellulose-like biopolymers such as 
chitin, chitosan, and microcrystalline cellulose on indomethacin, the adsorptive 
capacity was ranked in the order: chitosan greater than chitin greater than 
microcrystalline cellulose. All the adsorption isotherms were found to follow the 
Langmuir and the Freundlich equations. However, chitosan-acetate gel powders and 
chitosan powders with pre-added acetic acid and methanol did not follow these 
equations, due to gel formations that led to more adsorption of indomethacin on the 
interlayer space of the gel. The strong adsorption of indomethacin onto chitosan 
might result in difficult desorption of the drug from the poymer (64). 
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1.3.5. Characterization of polymers 
1.3.5.1. Light scattering 
 Light scattering is a technique widely used to characterize polymeric 
materials. Lasers are used as light sources in order to measure scattering at small 
angles to the beam. This is important since the data obtained must be extrapolated to 
zero concentration and zero-scattering angle using Zimm plots. The weight-average 
molecular weight is determined by this technique. Dynamic light scattering has been 
used to determine the number-average molecular weight and molecular weight 
distribution of polymers in solution (65, 66). 
 
1.3.5.2. Other methods 
The change in the molecular weight of Eudragit RS in microspheres was 
determined by a sedimentation equilibrium ultracentrifugation technique using a 
Beckman ultracentrifuge. The weight average molecular weight determined was 
10,000. Following irridiation this value had increased to 12,000 (67).  
Colorimetric ion-pair complexation method has been developed which 
provides a simple and rapid way of quantifying Eudragit RS100 and RL100 in 
pharmaceutical dosage forms (68). The quaternary ammonium groupings in these 
polymers appear to form an ion-pair complex with the dye tropaeolin OOO. When 
extracted into an organic phase, the optical density at 484 nm was linearly related to 
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polymer concentration. Good reproducibility, precision, and accuracy were 
demonstrated when the method was applied to a film-coated pellet formulation 
containing an interfering drug (promethazine hydrochloride). The method was 
sufficiently sensitive for the determination of polymer on a single dose unit of 
encapsulated beads. 
 
1.4. Characterization of Thermal Processing 
 
1.4.1. Plasticization efficiency 
Plasticization efficiency and polymer miscibility are two considerations when 
selecting an appopriate plasticizer material. These two properties are depending upon 
their chemical structures. One way to evaluate plasticization efficiency and 
miscibility is to determine the glass transition temperature (Tg) of the blend of the 
materials by differential scanning calorimetry (DSC).  The phase behavior may be 
conveniently determined by using the well-know single glass transition temperature 
criterion. When the glass transition of the mixture is intermediate to that of the 
individual components, this can often be used as an indication of miscibility (10). For 
an exacting polymer blend system where the Tg values of the two polymers are 
virtually coincident or similar, the aging studies are an additional useful technique to 
study polymer-polymer miscibility (69).  Plasticization efficiency can be deteremined 
by measuring the glass transition temperature (Tg) as a function of plasticizer 
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concentration in the polymer.  The glass transition temperature of two miscible 
materials can also be predicted by using the Gordon-Taylor equation (70).   
 
1.4.2. Thermal processing temperatures 
An attention must be paid when selecting a temperature to thermally process 
the drug and polymer. High processing temperatures are detrimental to the 
formulation components, whereas low temperatures make thermal processing hard to 
conduct due to the high resistence force of the unmelted or high viscosity materials 
exerted on the machinary.  In order to maintain the thermal and chemical stability of 
the formulation and also the ideal thermal processibility, the type and level of thermal 
processing aids, including plasticizers and thermal lubricants, are needed to optimize 
the thermal processing temperatures. The temperature range used for extrusion is 
typically 50 to 100°C above the Tg of the polymer (71). 
 
1.4.3. Melt-viscosity 
High molecular weight polymers (between about 10,000 and 40,000) usually 
generate high melt-viscosity due to the macromolecules are linked to their neighbors 
at many points.  Melt-viscosity of the materials in the formulation is directly related 
to its thermal processability.  High melt-viscosity results in a greater force 
requirement by the machinery to process the material and can result in poor product 
quality or even equipment damage. If the melt viscosity of the material is too low, 
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however, the final extrudate will lack the desired shape, size and appearance.  
Measurement of the force required to process the material (torque or amp) aids in the 
selection of the processing conditions for appropriate melt viscosity.  
In addition to the molecular weight and structure of the polymer, the 
rheological properties of polymer melt also depend upon processing temperature, 
pressure, the rate of shear, as well as upon the incorporation of various additives (46), 
which may provide us some solutions to enhance the thermal processing. 
 
1.5. Pharmaceutical Application of Hot-melt Extrusion 
 
Compared to the long history and wide application of hot-melt extrusion in the 
plastics industry, the use of this technology in the pharmaceutical industry is still at 
an early age. The pioneer research on the applications of hot-melt extrusion to prepare 
pharmaceutical dosage form was first reported by Speiser and coworkers in 1971 
(72).  They prepared sustained drug delivery systems containing some thermally 
stable epoxy resins by hot-melt extrusion.  
Follonier et al investigated several ways of modulating the release of 
diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared 
using polymeric materials (73). To investigate hot-melt extrusion as a new technique 
for producing sustained-release polymer-based pellets with a high loading of a freely 
soluble drug, four polymers and diltiazem hydrochloride as the model drug were 
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considered for the extrusion trials. Surface appearance of various formulations was 
examined and the porosity assessed by means of mercury porosimetry. The pellets 
produced exhibited a generally smooth surface and low porosity. A distinct structure 
was found for the poly(ethylene-co-vinyl acetate) (ethylene-vinyl acetate copolymer; 
EVAC)-based pellets. The overall porosity was less than 10%. In vitro release of the 
drug showed a biphasic profile with a slow diffusion-controlled phase following a 
much faster release. The release of diltiazem hydrochloride from EVAC-based hot-
melt extruded pellets of size 2x2 mm was less than 20% in 8 hours. The EVAC-based 
extrusion seemed most promising for further studies because of its low extrusion 
temperature, ease of processing, and slow release characteristics. It was concluded 
that hot-melt extrusion could be a simple method for producing sustained-release 
pellets with high loading of a freely soluble drug.  
Zhang and McGinity investigated the properties of polyethylene oxide (PEO) 
as a drug carrier and the release mechanism of chlorpheniramine maleate (CPM) from 
matrix tablets prepared by hot-melt extrusion. CPM and PEO were shown to be stable 
under the processing conditions. The molecular weight of the PEO, the drug loading 
percentage, and the inclusion of polyethylene glycol as a processing aid, were all 
found to influence the processing conditions and the drug release properties of the 
extruded tablets. Faster release of CPM from the matrix tablets was observed in acidic 
medium than in purified water and phosphate buffer (pH 7.4). Drug release from the 
matrix tablet was controlled by erosion of the PEO matrix and the diffusion of the 
drug through the swollen gel layer at the surface of the tablets. CPM was dispersed at 
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the molecular level in the PEO matrix at low drug loading level and recrystallization 
of CPM was observed at high drug loading levels (37). 
Zhang and McGinity have also investigated the properties of hot-melt 
extruded theophylline tablets containing poly(vinyl acetate) and the drug release 
mechanism of theophylline from matrix tablets prepared by hot-melt extrusion (36). 
The cylindrical extrudates were either cut into tablets or ground into granules and 
compressed with other excipients into tablets. Due to the low glass transition 
temperature of the PVAc, the melt extrusion process was conducted at approximately 
70°C. Theophylline was present in the extrudate in its crystalline form and was 
released from the tablets by diffusion. The Higuchi diffusion model and percolation 
theories were applied to the dissolution data to explain the drug release properties of 
the matrix systems. The release rate was shown to be dependent on the granule size, 
drug particle size, and drug loading in the tablets. Water-soluble polymers were 
demonstrated to be efficient release rate modifiers for this system. 
Liu and McGinity have investigated the influence of formulation factors on 
the physical properties of hot-melt extruded granules and compressed tablets 
containing wax as a thermal binder/retarding agent, and compared the properties of 
granules and tablets with those prepared by a high-shear melt granulation method 
(MG) (74). Powder blends containing phenylpropanolamine hydrochloride, Precirol 
and various excipients were extruded in a single-screw extruder at open-end 
discharge conditions. The extrudates were then passed through a 14-mesh screen to 
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form granules. The extrusion conditions and the optimum amount of wax to function 
as the thermal binder were dependent on the properties of the filler excipients. At the 
same wax level, drug release from tablets decreased in the order of using 
microcrystalline cellulose (MCC), lactose and Emcompress as the filler excipient. 
The observed differences in the dissolution properties of the tablets were due to the 
differences in the solubility, swellability and density of the filler excipients. 
Replacing Precirol with Sterotex K, a higher melting point wax, resulted in slightly 
increased dissolution rates, when the extrusion was performed at the same 
temperature conditions. Hot-melt extruded granules were observed to be less 
spherical than high-shear melt granules and showed lower values of bulk/tap 
densities. However, tablets containing MCC or lactose granules prepared by hot-melt 
extrusion (HME) exhibited higher hardness values. Slower drug release rates were 
found for tablets containing MCC by HME compared with MG. Analysis of the hot-
melt extruded granules showed better drug content uniformity among granules of 
different size ranges compared with high-shear melt granules, resulting in a more 
reproducible drug release from the corresponding tablets.  
An implant delivery system containing Melanotan-I, a superpotent 
tridecapeptide, and a biodegradable poly( , -lactide-co-glycolide) (PLGA) 
copolymer was prepared by the hot melt-extrusion method at the operating 
temperature of 45¯70°C (75). The PLGA polymers meet the requirements needed for 
a matrix delivery system, including mechanical properties, biodegradability, tissue 
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compatibility and ease of processing. The drug released from the depot implanted 
subcutaneously in guinea pigs exhibited a release profile extending over one month, 
in agreement with data from the in vitro studies.  
Hot-melt extrusion was used to prepare solid dispersions for poorly water-
soluble drug to improve the drug dissolution. 17 β-estradiol hemihydrate has a water 
solubility of 0.2-5µg/ml. A solid dispersion of this drug with PVP and Gelucire was 
prepared by hot-melt extrusion. The amount of drug released in pH 1.0 hydrochloric 
acid water solution from a solid dispersion containing 10% of 17 β-estradiol 
hemihydrate, 50% PVP and 40% Gelucire 44/14 was significantly higher compared to 
the pure, non-micronized drug (76). 
Forster et al reported that hot-melt extrusion can be used to enhance the 
bioavailability of poorly water-soluble drugs, including indomethacin, lacidipine, 
nifedipine and tolbutamide (77). Melt extrusion of these four poorly water-soluble 
drugs with PVP and PVP/VA resulted in glass solution formation depending on the 
temperature of the melt extrusion. When the temperature of the extrusion was too 
low, crystallinity was detected by powder XRD and DSC indicating incomplete 
melting of the drug. 
Repka and McGinity have investigated the influence of plasticizers and drugs 
on the physical-mechanical properties of hydroxypropylcellulose films prepared by 
hot-melt extrusion (78). Hydroxypropylcellulose (HPC) films containing drugs with 
either hydrophilic or hydrophobic plasticizers were prepared by a hot melt extrusion 
 43
process. Polyethylene glycol 8000 (PEG 8000) 2%, triethyl citrate (TEC) 2%, 
acetyltributyl citrate (ATBC) 2%, and polyethylene glycol 400 (PEG 400) 1% were 
the plasticizing agents studied. In addition, either hydrocortisone 1% or 
chlorpheniramine maleate (CPM) 1% was incorporated into the films as the model 
drug. The glass transition temperatures initially decreased with the inclusion of the 
drugs and plasticizers, however, after 6 months aging, films containing PEG 400 and 
hydrocortisone showed a marked increase in Tg. The films containing PEG 400 
showed physical-mechanical instability in all parameters studied. All extruded films 
exhibited a marked decrease in tensile strength in contrast to a large increase in 
percentage elongation when testing was performed perpendicular to flow versus in 
the direction of flow. In addition, a consistent film of HPC in the absence of drugs or 
plasticizers could not be extruded due to the excessive stress on the equipment. 
Although the percentage of CPM on aging remained fairly constant over the 
processing temperature ranges in this study, the hydrcortisone levels remaining in the 
extruded films during storage, demonstrated as a function of time and temperature. 
The influence of chlorpheniramine maleate (CPM) on the chemical and 
physical-mechanical properties of hydroxypropylcellulose (HPC) hot-melt extruded 
films containing CPM in concentrations of 1, 5, and 10 wt% was investigated. CPM 
functioned as an effective plasticizer, increasing percent elongation and decreasing 
tensile strength in a concentration dependent manner. All three concentrations of 
extruded films exhibited a 10- to 12-fold decrease in tensile strength in contrast to a 
fourfold increase in percent elongation when testing was performed perpendicular to 
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flow vs. in the direction of flow. The drug was also shown by XRD and DSC data to 
be in solution in the HPC matrix films up to the 10% level. In addition, CPM 
functioned as a processing aid in the extrusion of hot-melt films by stabilizing the 
weight-average molecular weight of HPC and allowing for film processing at lower 
temperatures (79). 
Films containing hydroxypropylcellulose (HPC) and polyethylene oxide 
(PEO) were prepared with and without Vitamin E TPGS as an additive. Conventional 
plasticizers including polyethylene glycol 400 (PEG 400), triethyl citrate (TEC), and 
acetyltributyl citrate (ATBC) were also incorporated into films containing a 50:50 
blend of HPC and PEO. The addition of 1, 3, and 5% Vitamin E TPGS, respectively, 
decreased the glass transition temperature of the extruded films containing either a 
50:50 or 80:20 ratio of HPC to PEO in an almost linear fashion. In addition, the 
presence of 3% Vitamin E TPGS lowered the Tg over 11°C when compared with the 
HPC/PEO 50:50 blend film without TPGS, thus functioning as a plasticizer. The 
tensile strength decreased with increasing concentrations of TPGS, and the 
percentage elongation increased over 3-fold when compared with the HPC/PEO film 
that contained no additives. The film containing 3% Vitamin E TPGS had a similar 
tensile strength to that of the films containing 3% PEG 400, and a 3-fold increase in 
percent elongation when compared with the films containing 3% TEC and 3% ATBC. 
In addition, the Vitamin E TPGS facilitated the processing of the HPC/PEO films by 
decreasing the barrel pressure, drive amps, and torque of the extruder equipment (42).  
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 The moisture absorption, physical-mechanical, and bioadhesive properties of 
hot-melt extruded hydroxypropylcellulose (HPC) films containing polymer additives 
were investigated. These additives included polyethylene glycol (PEG) 5%, 
polycarbophil 5%, carbomer 5%, Eudragit E-100 5%, and sodium starch glycolate 
(SSG) 5%. Although all films studied exhibited an increase in percent water content 
as the percent RH increased, the SSG containing film exhibited an almost three-fold 
increase in percent water content compared to that of the HPC/PEG film. The 
temperature storage condition of 40°C/100% RH (versus 25°C/100% RH) increased 
the percent water content of the SSG containing film. Percent elongation was highest 
for films containing polycarbophil 5% (without PEG). In addition, the HPC film 
containing polycarbophil 5% exhibited a greater force of adhesion and elongation at 
adhesive failure in vivo, and a lower modulus of adhesion when compared to the 
HPC/PEG film (80). 
The in vivo bioadhesive properties of hydroxypropylcellulose (HPC) hot-melt 
extruded films containing seven polymer additives on the epidermis of 12 human 
subjects was investigated. HPC films containing polyethylene glycol (PEG 3350) 
alone, Vitamin E TPGS (TPGS) 5%, sodium starch glycolate 5%, Eudragit E-100 5%, 
carbomer 974P and 971P 5%, and polycarbophil 5%, all with and without 
plasticizer, were prepared by hot-melt extrusion. The carbomer 971P and 
polycarbophil containing films were determined to have the highest force of adhesion 
and elongation at adhesive failure, and the lowest modulus of adhesion of all films 
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tested. The film containing carbomer 971P had a higher force of adhesion than the 
film containing 974P. In addition, films in one ethnic sub-group exhibited higher 
force of adhesion and elongation at adhesive failure than the other. Force¯deflection 
profiles obtained from these experiments indicate that the force of adhesion, 
elongation at adhesive failure and modulus of adhesion are a function of the polymer 
additive in the HPC extruded films. The incorporation of carbomer 971P and a 
polycarbophil into HPC films increased bioadhesion significantly when compared to 
the film containing HPC and PEG 3350. Differences in force of adhesion and 
elongation at adhesive failure were discovered between two ethnic sub-groups tested 
(81).  
 
1.6. Challenges with the Hot-melt Extrusion 
 
1.6.1. Characterization of the hot-melt extrudates 
 
1.6.1.1. Thermal and chemical stability 
During the hot-melt extrusion process, both polymeric materials and active 
drugs are subjected to both thermal stress and shear stress. The thermal stress is due 
to the high processing temperature associated with the hot-melt extrusion process. 
Depolymerization and thermal oxidation of the polymer may occur from high-
temperature processing. The shear stress imposed on the polymer by the rotating 
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screw during the extrusion process could also induce a physical scission of the 
polymeric chains. A limitation to hot-melt extrusion processing is the thermal and 
chemical stability of the drug and the carrier. The drug may decompose or evaporate 
if processing temperatures exceeds certain temperature. To maintain the thermal and 
chemical stability of all components is one of the major concerns with this process 
and the selection of suitable plasticizers and thermal lubricants can achieve this goal.  
Recently, hot-melt extrusion has been applied to the manufacture of solid 
dispersions. An important advantage of the hot-melt extrusion method over other 
thermal processing techniques is that the drug/carrier mixture is only subjected to heat 
for a few minutes, enabling both the drug and the carrier to remain thermally stable. 
The melt viscosity of acrylic polymers is more sensitive to temperature than that of 
most other thermoplastics. For accurate, consistent and reproducible results, good 
temperature control is required on all equipment.  
 
1.6.1.2. Aging effect  
 The change in the physicochemical and the drug release properties of a 
polymeric drug delivery system can be contributed to the change of the 
physicochemical properties of both the drug and the polymer.  
It is well known that the dispersed-phase particles tend to become larger on 
aging because the interfacial energy of the system is reduced by the concomitant 
reduction in interface area (11). The amorphous and other metastable crystalline 
forms of the dispersed drugs in solid dispersions are also subject to aging effect. 
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Significant crystallization rates of many materials from the amorphous state often 
occur above the glass transition temperature due to the existence of the sufficient 
molecular mobility to allow rapid nucleation and crystal growth. Water increases the 
crystallization rates of indomethacin from the amorphous state, presumably due to an 
increase in molecular mobility with a correspondingly marked reduction of Tg (82). 
Temperature was an important factor influencing the first-order transition rate of 
indomethacin from the amorphous form to the crystalline form (83). 
 For polymers in the formulation, the physical aging phenomenon results from 
the decrease in the free volume and accompanying decrease in molecular mobility 
(84). 
Curing has been shown to reduce the permeability of an Eudragit RS 30D 
polymeric film and to decrease the drug release rate constant of theophylline (85), 
demonstrating the aging phenomena of the polymer. For the hot-melt extrudated 
system, it is interesting to investigate the drug release from the extrudates following 
the post-processing thermal treatment. 
 
1.6.1.3. Drug release mechanism 
Following the thermal extrusion processing, the entanglement of the polymer 
was increased and the free volume of the extrudates was decreased. Therefore, the 
permeability of the drug through the polymeric system was decreased. Suitable drug 
release model should be explored to fit the drug release profiles. For example, the 
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release of diltiazem hydrochloride from hot-melt extrudated pellets containing 
Eudragit RS PO followed a biexponential release behavior (73). This could be 
explained by the rapid release of the easily accessible drug at the surface of the 
pellets, followed by a slow second phase where diffusion prevails. 
 
1.6.2. Problems with thermal processing 
1.6.2.1. Processibility 
Polymers behave very differently in the molten state than in solution, 
primarily due to the existence of the intermolecular interference from their neighbors 
in the molten state (71). A very important feature of high-molecular-weight polymers 
is their ability to be in a rubbery state, which is between the fluid state and glassy 
state.  
Processibility is directly related to the rheological properties of polymer melt, 
which depend upon processing temperature, pressure, the rate of shear, the molecular 
weight and structure of the polymer, as well as upon the type and concentration of 
various additives (46).  
Effect of temperature on viscosity 
Under typical hot-melt extrusion processing conditions, polymer melts behave 
as pseudoplastic fluids. The melt viscosity is a measure of the frictional forces 
between the molecules in a liquid. The Willams-Landel-Ferry equation expresses the 
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viscosity at low rates of shear for amorphous polymers at temperatures less than 
100°C above their Tg  (86).  
log10[η  (T)/ η  (Tg)] ≅ [- 17.44 (T-Tg)] / [51.6+(T-Tg)] 
where η  (T) is the melt viscosity of materials at temperature T in degrees Kelvin, η  
(Tg) is the melt viscosity of materials at the glass transition temperature Tg in degrees 
Kelvin.  
For polymer fluids at temperatures far above the glass transition temperature 
or the melting point, the viscosity follows the Andrade or Arrhenius equation: 
η ≅ K eE/RT 
where K is a constant at a given shear stress for a given polymer, E is the activation 
energy, R is the gas constant and T is the temperature in degrees Kelvin.  
Clearly, increasing temperature is an effective means of decreasing melt 
viscosity in processing operation. Although the melt viscosity decreases with 
increasing temperature, two drawbacks are related to the increases in temperature. 
First, it takes time and costs money to put in and take out thermal energy. Second, 
excessive temperatures can lead to degradation of the polymer. There is certainly an 
upper limit to the processing temperature we can use for a particular polymer which 
depends upon the degradation temperature.  
Effect of pressure on viscosity 
For all fluids, viscosity increases with increasing pressure as the free volume 
is decreased which facilates the molecular slippage. With polymer melts, because of 
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their relative incompressibility, the effect becomes noticeable only at fairly high 
pressure (86). The pressure can be quite high in extruders and high pressure would 
result in slight increase in both Tg and Tm, causing the viscosity to increase 
tremendously as either is approached. The high viscosity due to pressure may exist, 
but the increase may be partly offset by viscous heating of the polymer in the 
equipment. The shear heating of the polymer in the equipment raises the temperature 
above the indicated value so that the viscosity may be lowered by an amount 
comparable to the increase due to the pressure. The high shear rate dependence of 
viscosity also obscures the effect of pressure (46). 
Effect of rate of shear on viscosity 
The viscosity of polymer melts is shear-rate dependent and is described by 
(87): 
η = Kϒ n-1 
where η represents the viscosity of the polymer melt; ϒ is the shear rate imposed on 
the polymer; K, an exponential function of the temperature, depends on the properties 
of the polymer; and n is a constant ( in the range of 0.25 to 0.9 for the polymer melt) 
which depends only on the properties of the polymer. 
A polymer melt at lower shearing rate have a higher concentration of 
entanglements than that at higher shearing rate. Entanglements not only increase 
elasticity, but they also increase the viscosity because it becomes more difficult for 
flow to occur by relative motion of the molecules when they are entangled (46).  
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Effect of molecular weight on viscosity 
The relationship between the melt viscosity and the molecular weight of the 
polymer is governed by different equations depending upon the molecular weight of 
the polymer. Below a critical molecular weight, the viscosity of a molten polymer 
depends upon local features such as free volume, which governs the melt viscosity of 
small molecules and results in a practically linear dependence of viscosity on 
molecular weight. At molecular weight above a critical molecular weight, the 
entanglements of the chains with one another becomes important and the viscosity at 
low rates of shear depends upon weight average molecular weight to a power equal to 
about 3.4 or 3.5 (46, 88). A high molecular weight polymer macromolecule is linked 
to its neighbors at many points. The three-dimensional network is quite 
homogeneous, and its links can withstand high stresses without failure because the 
loads are statistically distributed uniformly over a large number of links (89). 
Therefore, higher molecular weight polymers are more viscous and difficult to 
extrude.  For most polymers, the critical molecular weight is between about 10,000 
and 40,000. For polymethyl methacrylate, the critical molecular weight is 10,400 
(46).  
This would make the melt processing of high molecular weight polymers an 
imposing task. Accordingly, hot-melt extrusion of the high molecular weight polymer 
is a challenge for making pharmaceutical delivery systems. 
Effect of plasticizers and lubricants on viscosity 
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When a polymer is mixed with a plasticizer, the mixture has a Tg between the 
values of the two components. The W-L-F equation approximately accounts for the 
decrease in viscosity as a result of lowering Tg. 
The function of thermal lubricants is to reduce the apparent viscosity of a 
polymer or to improve the surface appearance of a finished product made by 
extrusion. 
Liquid plasticizers are used to reduce polymer Tg and processing temperature. 
However, difficulty in formulation mixing will occur when high levels of liquid 
plasticizers are used.  Consequently, to enhance the thermal processibility, a solid 
thermal lubricant can be added to the formulation in conjunction with the liquid 
plasticizer to lower the melt viscosity, thereby preventing the need for high levels of a 
liquid plasticizer.  
 
1.6.2.2. Miscibility 
Hot-melt extrusion does not always require formulation components to be 
miscible, however, for the manufacture of solid solutions it is a prerequisite for the 
drug and the carrier to be miscible in the molten form.  Poor miscibility between the 
drug and the carrier usually leads to a product that is not molecularly dispersed. By 
selecting polymeric carriers having similar solubility parameters as the drug, this 
problem can be solved.  A single Tg determined for a blend of two materials with 
different Tgs indicates the thermal miscibility of the materials.   
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To achieve a specific drug delivery rate, sometimes more than one type of 
polymer needs to be incorporated into the formulation. Polymer-polymer miscibility 
is generally considered as a result of specific interaction between polymer segments. 
The specific interactions include donor-acceptor, dipole-dipole, hydrogen-bonding, 
ion-ion, acid-base, and ion-dipole interactions (90). It is known that proton acceptor 
polymer like PVP forms miscible blends with hydroxyl-containing polymers such as 
poly(vinyl phenol), poly(vinyl alcohol), poly(hydroxy ethyl methacrylate), etc (91). 
The specific interaction is hydrogen bonding. Polymer-polymer miscibility can be 
detected by a number of techniques such as DSC, neutron scattering, morphology 
studies by optical and electron microscopy, dynamic mechanical measurements, 
infrared spectroscopy, ultrasound, and viscometry. Miscibility characteristics of 
cellulose acetate phthalate (CAP) and poly(vinyl pyrollidone) (PVP) have been 
investigated by solution viscometric, ultrasonic, and differential scanning calorimetric 
(DSC) methods. The results obtained reveal that CAP forms a miscible blend with 
PVP in the entire composition range. Compatibility may be due to the formation of 
hydrogen bonding between the carbonyl group of PVP and the free-hydroxyl group of 






CHAPTER TWO: RESEARCH OBJECTIVES 
 
2.1.  Overall Objective 
The overall objective of this research project is to investigate the influence of 
hot-melt extrusion on the properties of polymeric controlled release drug delivery 
systems. This overall objective can be subdivided into the following supporting 
objectives. 
 
2.2. Supporting Objectives 
 
2.2.1. Investigate the properties of controlled release chlorpheniramine maleate 
tablets containing Eudragit RS PO prepared by thermal processing 
2.2.1.1. Investigate the plasticization effect of a solid drug 
Eudragit RS PO is a copolymer of acrylic and methacrylic esters with a low 
content of quaternary ammonium groups. It has been used to prepare matrix tablets by 
direct compression and wet granulation techniques. The objectives of this study were 
to demonstrate the influence of the in situ solid-state plasticization of 
chlorpheniramine maleate (CPM) on Eudragit RS PO and to investigate the 
physicochemical properties of the resulting composite tablets.  
2.2.1.2. Investigate the plasticization effect by a liquid plasticizer 
 56
A water-soluble liquid plasticizer, triethyl citrate (TEC), was selected as a 
candidate compound to investigate the plasticization effect on the Eudragit RS PO 
by differential scanning calorimetry (DSC). These findings will be related to the 
results obtained from the thermal processing parameters and drug release studies. 
2.2.1.3. Investigate the thermal stability 
Thermal stability is a primary concern for thermal processing. The thermal 
stability of all the materials used in hot-melt extrusion process will be investigated by 
thermogravimetric analysis (TGA) and HPLC. The materials include CPM, TEC and 
Eudragit RS PO. 
2.2.1.4. Investigate the preparation techniques on drug release 
Drug release rate is one of the most important parameters for a polymeric drug 
delivery system. The influences of TEC level and CPM level on the drug release from 
directly compressed tablets, tablets made from hot-melt granulation, and hot-melt 
extruded tablets will be investigated to compare the influence of processing on the 
rate and mechanism of drug release.  
2.2.1.5. Quantitate of the TEC leached from the hot-melt extrudates during 
dissolution testing 
Leaching of TEC from Eudragit RS 30D film coatings has been reported in 
the literature, suggested that TEC may also leach from the hot-melt extrudates.   
Determination of the amount of TEC released from the extrudates will aid in 
 57
understanding of the drug release mechanism.   A HPLC method will be developed to 
determine the amount of TEC released from the hot-melt extrudates. 
 
2.2.2. Investigate the influence of post-processing thermal treatment on the 
properties of controlled release CPM tablets containing Eudragit RS PO 
prepared by thermal processing 
2.2.2.1. Investigate the post-processing thermal treatment on drug release 
In addition to hot-melt extrusion and hot-melt granulation, curing or post-
processing thermal treatment will be employed to facilitate the aging process. Curing 
at temperatures above the glass transition temperature of a coating polymer 
significantly enhances film formation by ensuring full coalescence of the latex 
particles. Curing has been shown to reduce the permeability of the film and to result 
in a decrease in the drug release rate constant. It was also reported that post-thermal 
treatment of tablets containing poly(DL-lactic acid) (PLA) at temperatures above the 
Tg of PLA significantly reduced the drug release rate from the matrix tablets. 
High shear hot-melt granulation and hot-melt extrusion are two thermal 
processing techniques that utilize different temperature ranges.  Both techniques will 
be employed to prepare the CPM tablets resulting in different polymeric structures. 
Curing these tablets and determining the drug release rate will facilitate in 
understanding of the effect of these two thermal processes on the rates and 
mechanisms of drug release.   
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2.2.2.2. Investigate the microstructures of the hot-melt extrudates 
  High shear hot-melt granulation and hot-melt extrusion techniques result in 
products having unique microstructures which influence drug release profiles. 
Scanning electron microscopy (SEM) was used to investigate the microstructures of 
the polymeric drug delivery systems after thermal processing.  
2.2.2.3. Investigate the crystallinity of the hot-melt extrudates 
Changes in CPM crystalline structure following thermal processing of the 
acrylic drug delivery systems was investigated using powder X-ray diffractometry. 
 
2.2.3. Investigate the influence of a lipophilic thermal lubricant on the processing 
conditions and drug release properties of chlorpheniramine maleate tablets 
prepared by hot-melt extrusion 
To facilitate the hot-melt extrusion thermal processing a pharmaceutical 
thermal lubricant, glyceryl monostearate (GMS), will first be used in hot-melt 
extrusion processing. The influence of GMS level on the properties of the 
chlorpheniramine maleate (CPM) controlled release tablets prepared by hot-melt 
extrusion will be studied. The melt viscosity, processing amps, and pre-die pressure 
will be recorded to investigate the influence of GMS on the processibility. 
Dissolution rate, GMS and Eudragit RS PO compatibility, drug amorphous state and 
microstructure of the extrudate will also be investigated to explain the thermal 
lubrication mechanism and drug release properties.  
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2.2.4. Investigate the influence of plasticizers on the dissolution properties of a 
highly water-soluble drug from Eudragit RS 30 D coated pellets and hot-melt 
extruded tablets containing Eudragit RS PO 
The influence of plasticizer level on Eudragit RS PO were investigated for 
two thermal processes: hot-melt extrusion and film coating. Formulations containing 
diltiazem hydrochloride (DTZ), a highly water-soluble model drug, was hot-melt 
extruded.  Additionally, pellets containing DTZ were film coated with Edragit RS 
30D containing different plasticizer levels in a fluidized bed coating machine.  For 
highly water-soluble drugs, much attention should be given to minimize the burst 
effect, which is a fast release phenomenon during the early releasing time of the 
controlled release dosage forms. DSC was employed to investigate the plasticizing 
effect of DTZ, and TEC on Eudragit RS PO.  TGA was used to study the thermal 
stability of the model drug and the plasticizers. A HPLC method was qualified to 
measure the amount of DTZ released from the delivery systems, as well as to monitor 
the chemical stability of the DTZ in the hot-melt extrudates. SEM was employed to 
investigate the coating film formation and the microstructure of the hot-melt 
extrudates. X-ray diffractometry was used to investigate the crystallinity of the model 
drug following hot-melt extrusion. 
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2.2.5. Investigate the properties of polymeric delivery systems containing a 
poorly water soluble drug and Eudragit RD 100 prepared by hot-melt 
extrusion 
Formulation of poorly water-soluble drugs for oral delivery presents a 
challenge to pharmaceutical scientists. The solid dispersion technique is one of the 
most readily used methods to improve drug dissolution rate.  The major concerns with 
solid dispersions are in the ability to scale-up the manufacturing process and to 
preserve the physical stability of the dispersions. The application of the hot-melt 
extrusion technique to produce solid dispersions is a particularly important 
breakthrough for the scale-up of solid dispersion manufacturing. The recrystallization 
of the water insoluble drug from the supersaturated solid solution can be inhibited by 
incorporation of some polymers, such as PVP.  
Indomethacin (IDM), a poorly water-soluble, non-steroidal anti-inflammatory 
agent was used as a model drug to polymeric solid dispersions by hot-melt extrusion.  
DSC was employed to investigate the plasicizing effect of IDM on Eudragit RL PO.  
Drug and polymer interaction was studied by determining the adsorption of the IDM 
on the polymer. Drug release mechanism was investigated. TGA was used to study 
the thermal stability of the model drug, and a HPLC method was developed to 
determine the chemical stability of the model drug following thermal processing. 
SEM was employed to investigate the microstructure of the hot-melt extrudates, and 
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X-ray diffractometry was used to investigate the crystallinity of the model drug 
following hot-melt extrusion.  
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The thermal acrylic polymers that were selected for this study included 
Eudragit RS PO, Eudragit RL PO, Eudragit RD 100, Eudragit S 100, Eudragit 
L 100, and Eudragit RS 30D. They were donated by Röhm America, Inc. 
(Piscataway, NJ). 
Eudragit RS PO and Eudragit RL PO are copolymers of acrylic and 
methacrylic esters. These polymers have a similar chemical structure. However, 
Eudragit RS PO has a lower content of quaternary ammonium groups than 
Eudragit RL PO, therefore, Eudragit RS PO has a lower water permeability than 
Eudragit RL PO.  They are used for controlled drug release. 
Eudragit RD 100 contains 91% of Eudragit RL PO and 9% of sodium 
carboxymethylcellulose. This material is currently used for the film coating of 
immediately release solid dosage forms.  
Eudragit L 100 and Eudragit S 100 are anionic copolymers containing 
methacrylic acid and methyl methacrylate with a carboxyl acid functional group.  The 
ratio of the free carboxyl groups to the ester groups is approximately 1:1 in Eudragit 
L 100 and about 1:2 in Eudragit S 100.  Therefore, Eudragit S 100 has a lower 
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permeability than Eudragit L 100.  Three model drugs, including chlorpheniramine 
maleate (CPM), diltiazem hydrochloride (DTZ), and indomethacin (IDM) were 
purchased from Spectrum Quality Products, Inc. (Gardena, CA). The other materials 
were kindly supplied by various manufactures: triethyl citrate (TEC), Morflex, Inc. 
(Greensboro, NC); Cab-O-Sil M-5P, Cabot Corporation (Tuscola, IL). glyceryl 
monostearate (GMS), Condea Vita Company (Westwood, NJ); Altalc 500V, Luzenac 
America, Inc. (Englewood, CO); Lactose monohydrate, Foremost Farms USA, 
(Baraboo, WI); PVP 90F, BASF, (Ludwigshafen, Germany). Pluronic F68, BASF 
(Mt.  Olive, NJ); Avicel PH-101, FMC Corporation (Newark, DE); L-HPC LH-21, 




3.2.1. Preparation of hot-melt extruded tablets 
A dry powder blend of CPM, or DTZ or IDM, and Eudragit RS PO or 
Eudragit RD 100 was mixed using a Model RSI 3VG Robot Coupe Vertical Batch 
Processor (Robot Coupe Scientific Industrial Division, Ridgeland, MS) for 2 minutes. 
Varying amounts of TEC, 0%, 4%, 8% (7% TEC for CPM, since CPM had a solid-
state plasticization effect on the polymer and made the polymer sticky when more 
than 7% TEC was used) were added to the dry powder blend at the speed of 1500rpm, 
and mixed for additional 2 minutes. The TEC plasticized powder blends were added 
to the hopper of a vertical single screw Randcastle Model RCP-0750 Microtruder 
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(Randcastle Extrusion Systems Inc., NJ) with a screw diameter of 0.750 inches and a 
working length to diameter ratio of 24 (Randcastle Extrusion Systems Inc., NJ). The 
operating temperatures for DTZ, CPM and IDM at different zones of the extruder are 
listed in Table 3.2.1. The screw rotation speed was 20rpm and the cylindrical die 
diameter was 6.0mm. CPM, DTZ, and IDM hot-melt extrudates were produced at the 
opening of the die and were cut manually into tablets with a weight of approximately 
100mg.  
 
3.2.2. Preparation of hot-melt extruded granules 
Hot-melt extruded granules containing CPM were made with a model RCP-
2.0 Pelletizer (Randcastle Extrusion Systems Inc., NJ) by pelletizing the hot-melt 
extrudates prepared by the process described in section 3.2.1.. Granules in the 20-40 
mesh range (850-425µ) were retained for further evaluation.  
Hot-melt extruded granules containing IDM were reduced in size using a 
mortar and pestle.  Granules measuring 20-40 meshes and 40-60 meshes were 
retained for further evaluation.   
 
3.2.3. Preparation of high shear hot-melt granules 
Granules were prepared by a high shear hot-melt granulation process using a 
Robot Coupe Vertical Batch Processor (Model RSI 3VG, Robot Coupe Scientific 
Industrial Division, Ridgeland, MS). Three S-blades were assembled in the three-liter 
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stainless steel chamber. The processing temperature was maintained at 60°C by 
circulating Thermal M fluid (100°C) (Julabo USA Inc., Kutztown, PA) in the jacket 
surrounding the chamber.  The temperature inside the chamber was monitored using a 
thermal probe.  The CPM and Eudragit RS PO were blended at a speed of 1500rpm 
for two minutes.  During this time, TEC was also incorporated into the powder blend.  
The blended material was heated until granules were formed between 60°C and 70°C.  
After mixing for 10 minutes, the granules were cooled to 25°C.  Granules in the 20-
40 mesh range (850-425µ) were retained for further study. 
 
3.2.4. DTZ beads preparation 
A dry powder blend of diltiazem hydrochloride (30%), lactose monohydrate 
(32%) and Avicel PH-101 (35%) was mixed for 20 minutes using a twin-shell 
blender. 3% PVP 90F (in 10% water solution) as granulating binder was added during 
the wet massing process. The moistened mass was extruded using a LCI Benchtop 
Granulator (LCI Corp., Charlotte, NC) with a screen opening of 1.0mm. The rotation 
speed of the impeller was controlled at 25rpm. The extrudates were spheronized using 
a Caleva Model 120 Spheronizer (G. B. Caleva Ltd., Dorset, England) by setting the 
spheronization speed and residence time at 1000rpm and 5 minutes, respectively. The 
wet spheronized beads were then dried at 40°C for 48 hours. Beads in the particle size 
range of 14-20 mesh were used for coating. 
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3.2.5. Film-coating of DTZ beads 
3.2.5.1. Procedures of preparing the coating dispersion 
 A suspension containing 15% solid materials was made by adding Eudragit 
RS 30D, 50% Talc, and 10%, 15%, or 20% TEC in distilled water.  The amount of 
TEC and Talc was based on the solid polymer weight.  The suspension was mixed by 
using a stir bar for 60 minutes. 
 
3.2.5.2. Film coating 
 250g of DTZ beads in the particle size of 14-20 mesh were coated with 
plasticized aqueous coating dispersion in an Aeromatic-Fielder AG Model Strea 1 
coating machine with the coating conditions listed in Table 3.2.2. 
The aqueous dispersion was stirred continuously during the coating process. 
The coated beads were dried on trays in an oven at 40°C for 24 hours. The dried 
coated beads were stored in a desiccator for further evaluation. 
 
3.2.6. Compressed tablets preparation 
High shear hot-melt granules, hot-melt extruded granules containing CPM as 
well as a dry powder blend of CPM and excipients including the plasticizer TEC 
(High shear blending was used for the incorporation of the TEC into the dry powder 
blend) were compressed into tablets (6mm die) on a Carver laboratory press (Fred 
Carver Inc.) with a compression force of 2000kg.  High shear blending of the powder 
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mix with the TEC was conducted with a Robot Coupe Vertical Batch Processor for 2 
minutes to ensure a uniform distribution of the TEC throughout the powder. The 
tablet weight was approximately 100mg. 
Tablets containing IDM were prepared using a Carver laboratory press (Fred 
Carver Inc.).  A blend of 250mg hot-melt extruded granules containing 75mg IDM, 
225mg of Avicel PH-101 and 25mg of L-HPC LH-21 was transferred to a 6mm die 
and compressed with a compression force of 400Kg.  The prepared tablet weight was 
approximately 500mg with the hardness of about 15Kg. 
 
3.2.7. Post-processing thermal treatment 
Tablets containing CPM were placed in open glass vials and stored at 60°C. 
After storage for 0.25, 0.5, 1.0, 4.0, and 24 hours, the drug release properties of the 
tablets were determined. 
 
3.2.8. Determination of the hot-melt extrusion processing parameters for 
Eudragit RS PO 
A Randcastle vertical single screw Microtruder Model RCP-0750 
(Randcastle Extrusion Systems Inc., NJ) with a screw diameter of 19.05 millimeters 
and a working length to diameter ratio of 24 was used to determine the processing 
parameters. The screw rotation speed was 20.0rpm and the die diameter was 6.0 
millimeters. Both the drive AMPS and the pre-die pressure for Eudragit RS PO were 
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determined during thermal processing for the formulations containing Eudragit RS 
PO as a fuction of the level of TEC or GMS. 
 
3.2.9. Determination of the hot-melt viscosity 
The melt viscosity of the materials used was determined by using a model 
EPL-V5501 Electronic Plasti-Corder Torque Rheometer (C.W. Brabender 
Instruments Inc., South Hackensack, NJ). The processing temperatures of zone 1, 
zone 2, and zone 3 were set at 110°C, 130°C, and 140°C respectively. The rotation 
speed of the screw was 30rpm. Torque values were determined during the thermal 
processing for the powder blends containing Eudragit RS PO with different level of 
TEC or GMS. 
 
3.2.10. Particle size analysis 
 IDM, Eudragit RD 100, Eudragit RL PO was dispersed in distilled water 
separately in triplicate. The particle size of the materials was determined using a 
ZetaPlus Zeta potential Analyzer (Brookhaven Instruments Corporation, Holtsville, 
NY) with a BIC particle sizing software. 
 
3.2.11. True density determination 
Approximately 3-5g of IDM, Eudragit RD 100, Eudragit RL PO was 
weighed and a helium AccuPyc 1330 pycnometer (Micromeritics Instrument 
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Corporation, Norcross, GA) was employed to determine the true density of IDM, 
Eudragit RD 100, and Eudragit RL PO in triplicate.   
 
3.2.12. Modulated differential scanning calorimetry 
A modulated differential scanning calorimeter with a DSC 2920 Module 
Software Version 1.1 (TA Instruments, Model DSC 2920 Modulated DSC) was used 
to determine the solid-state plasticization effect of CPM on the Eudragit RS PO, the 
plasticization effect of TEC on the Eudragit RS PO, the miscibility of GMS with 
Eudragit RS PO, the solid-state plasticization effect of DTZ on the Eudragit RS 
PO, as well as the melting point of IDM and the solid-state plasticization effect of 
IDM and Pluronic F 68 on the Eudragit RL PO. Approximately 5-10mg of sample 
was accurately weighed and hermetically sealed in an aluminum pan.  The sample 
was equilibrated at –10°C for 2 minutes.  The temperature of the samples was then 
ramped from –10 to 160°C at a rate of 5.0°C/min.  Modulation was set at +/- 1.0°C 
every 60 seconds.  The samples were cycled twice to remove thermal history.  The 
glass transition temperature was measured in the second cycle as the step transition in 
the plot of reversible heat flow vs temperature.  The MDSC was calibrated using an 
indium standard prior to sample analysis. 
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3.2.13. Thermogravimetric analysis 
A TGA 7 (Perkin Elmer) was employed to investigate the thermal stability of 
Eudragit RS PO, Eudragit RL PO, Eudragit RD 100, Eudragit S 100, Eudragit 
L 100, CPM, DTZ, IDM, GMS, and TEC. Samples were maintained at 50°C for 1 
minute and then heated to 600°C at a heating rate of 10°C/min. For the dynamic 
stability studies, samples were held at either 120°C, or 140°C, 160°C for 10 minutes 
and the percentage weight loss was recorded. 
 
3.2.14. Chemical stability  
3.2.14.1. Chemical stability of DTZ following hot-melt extrusion 
10mg of the physical mixture and extrudate samples equivalent to about 
3.0mg of DTZ prior to and following hot-melt extrusion were accurately weighed and 
transferred to a 100ml volumetric flask respectively. Samples were dissolved with 
20ml ethanol first and then pH 7.4 phosphate buffer was added to volume. Samples 
were filtered with a 0.45µm nylon filter (Whatman Inc., Clifton, NJ) and determined 
using the HPLC method described in section 3.2.18.  
 
3.2.14.2. Chemical stability of IDM following hot-melt extrusion 
 Samples were dissolved with 20ml ethanol in a 100ml volumetric flask, then 
pH 7.4 phosphate buffer was added.  Samples were filtered with a 0.45µm nylon filter 
and determined by the HPLC method described in section 3.2.18. 
 71
 
3.2.15. X-ray diffractometry 
An APD 3520 Philips X-ray diffractometer with a PW 1720 X-ray generator 
and a PW 1710 diffractometer control was employed to study the crystallinity of 
CPM, DTZ, IDM, and the model drug with Eudragit RS PO or Eudragit RD 100 in 
a physical mixture, hot-melt granules, and hot-melt extruded granules. The generator 
operating voltage and current were 40KV and 40mA, respectively. The scanning 
speed was 2°/min, and the 2θ scanning range was from 5° to 50°. 
 
3.2.16. Scanning electron microscopy 
Samples of hot-melt extrudates, hot-melt granules, and Eudragit RS 30D 
coated pellets were coated with gold-palladium for 60 seconds under an argon 
atmosphere using a Pelco Model 3 sputter coater (TED Pella Inc., Tustin, CA) in a 
high vacuum evaporator equipped with an omni-rotary stage. The morphologies of 
the samples were investigated by using a Hitachi S-4500 Scanning Electron 
Microscope (Hitachi, Ltd. Ibaraki-Ken, Japan) at 15KV at two magnifications (100X 
and 1000X). 
 
3.2.17. Dissolution studies 
The release of CPM, TEC, DTZ, and IDM from the sustained release tablets 
or granules were determined by using the VanKel 7000 dissolution system with a 
 72
VanKel 7500 temperature control system and a VanKel 8000 autosampler according 
to the USP methods with the experiment conditions listed in Table 3.2.3. Samples 
were passed through a 10µ filter and analyzed using UV or the HPLC methods 
described in section 3.2.18. The experiments were conducted in triplicate.  
To investigate the influence of pH on the IDM release from hot-melt granules, 
a USP 24 apparatus III method was used with a VanKel Bio-Dis II with the following 
parameters.  250ml of different pH release media pH 1.2 (0~2h), pH 5.0 (2~4h), pH 
6.8 (4~8h), pH 7.4 (8~12h) maintained at 37°C.  Dipping rate was 20 dips per minute.  
Samples were collected and filtered through a 0.45µm filter at predetermined time 
intervals and analyzed by the HPLC method described above.  The experiments were 
conducted in triplicate.   
 
3.2.18. HPLC method for TEC 
A HPLC method was used to determine the release of TEC from the hot-melt 
extrudates (92). The stability indicating HPLC methods for CPM, DTZ, and IDM 
were based on the USP methods (93). 
The chromatographic system consisted of a Waters 501 HPLC pump, a 
Waters 486 tunable absorbance detector set at 220nm, a Waters 712 WISP sample 
injector, and a Waters C18 3.9×300mm µBondabpak analytical column (10µm). The 
experiment conditions are listed in Table 3.2.4. Linearity of the system was 
demonstrated over the working sample concentration range with a correlation 
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coefficient of 0.99. A lack of interference from the other ingredients was 
demonstrated, and the reproducibility of the system for multiple injections (n=6) was 
less than 0.5% relative standard deviation. 
 
3.2.19. Adsorption of indomethacin on the acrylic polymers 
2.5, 5.0, 10.0, and 15.0mL of 100.0µg/mL IDM pH 6.8 phosphate buffer 
solution and 17.5, 15.0, 10.0, and 5.0 mL of pH 6.8 phosphate buffer solution were 
added into each of the 4 test tubes respectively in triplicate. Either 0.20g of the 
Eudragit RD 100, or 0.18g of the Eudragit RD 100 and 0.02g Eudragit S 100, or 
0.18g of the Eudragit RD 100 and 0.02g Eudragit L 100 was added into each set of 
the test tubes. These test tubes were put into a shaking air bath thermostated at 37°C 











CHAPTER FOUR: RESULTS AND DISCUSSION 
 
4.1. Solid-state plasticization of an acrylic polymer with 
chlorpheniramine maleate and triethyl citrate 
 
Plasticizers are incorporated into pharmaceutical polymers to facilitate 
thermal processing (42), to modify drug release from polymeric systems (43, 45, 94, 
95) and to enhance the mechanical properties (42, 45, 96, 97) and surface appearance 
of the dosage form (98). When incorporated into a polymeric material, a plasticizer 
improves the workability and flexibility of the polymer by increasing the 
intermolecular separation of the polymer molecules (39). This results in a reduction in 
elastic modulus, tensile strength, polymer melt viscosity and glass transition 
temperature (Tg). The polymer toughness and flexibility is improved and lower 
thermal processing temperatures can be empolyed (87). For instance, pharmaceutical 
polymers used in film coating typically require a plasticizer in order to reduce 
brittleness and to enhance polymer coalescence and film formation (99). The 
plasticizer reduces both the glass transition temperature of the polymer and the 
minimum film formation temperature.  As a result, the temperature required for film 
coating is reduced.  
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In selecting the appropriate plasticizer for a polymeric material, the 
plasticization efficiency and compatibility must be considered which may be 
determined by measuring the glass transition temperature of the polymeric material as 
a function of plasticizer concentration.  Differential scanning calorimetry (DSC) is 
typically used to measure the polymer glass transition temperature, however, this 
technique is not always sensitive enough to identify Tg’s for certain polymers.  
Modulated differential scanning calorimetry (MDSC) has been shown to be more 
effective in separating thermal events, and provides greater resolution and sensitivity 
due to the application of a modulated rather than a linear temperature program (100, 
101). A second run is performed to erase the different thermal histories of the samples 
(102). 
Wu and McGinity reported that solid non-traditional plasticizers including 
methylparaben and drugs such as ibuprofen and chlorpheniramine maleate were able 
to plasticize and lower the glass transition temperature of polymeric films prepared 
from aqueous latex dispersions of Eudragit RS 30 D (45). Eudragit RS PO is a 
copolymer of acrylic and methacrylic esters with a low content of quaternary 
ammonium groups. It has been used to prepare matrix tablets by direct compression 
(103), and wet granulation techniques (104, 105).  
Hot-melt extrusion is one of the most widely applied processing techniques in 
the plastics industry. For pharmaceutical systems, several research groups have 
recently demonstrated that thermal processing of pharmaceutical powders is a viable 
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method to prepare granules, sustained release tablets (3, 36, 37) and transdermal drug 
delivery systems (42, 79-81). For pharmaceutical applications, hot-melt extrusion 
offers many advantages over traditional processing techniques. Solvents and water 
are not needed for processing, therefore fewer processing steps are needed and time-
consuming drying steps are eliminated. There are no requirements on the 
compressibility of the active ingredients and the entire procedure is simple, 
continuous and efficient (3).  
The objectives of this study were to demonstrate the influence of the in situ 
solid-state plasticization of chlorpheniramine maleate (CPM) on Eudragit RS PO 
and to investigate the physicochemical properties of the resulting composite tablets. 
Tablets were prepared by hot-melt extrusion and by direct compression. In addition, 
tablets were also compressed from granules prepared by a high shear hot-melt 
granulation technique.  CPM was used as both a model drug and as a solid-state 
plasticizer in this study.  A liquid plasticizer, triethyl citrate (TEC), was also 
incorporated into the formulations. Plasticization effect and the microstructure of 
these composites were investigated to explain the drug release mechanism from 
tablets prepared by the different technologies. 
 
4.1.1. Plasticization and drug release 
4.1.1.1. Influence of TEC concentration on drug release 
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 The profiles in Figure 4.1.1 demonstrate the influence of TEC levels on the 
dissolution properties of directly compressed tablets formulated with a dry powder 
blend of CPM and excipients or granules prepared by high shear hot-melt granulation.  
Drug release was greater than 80% in 2 hours for tablet formulations containing no 
TEC.  Tablets formulated using hot-melt granules containing no TEC released CPM 
faster than tablets of the dry powder blend.  Due to the loss of surface moisture during 
the hot-melt granulation process, no interaction between drug and polymer was 
observed when TEC was not present in the formulation, resulting in a faster release 
rate of drug from tablets containing granules prepared by high shear hot-melt 
processing.  
When TEC was incorporated into the formulations, the drug release rate 
decreased for both tablet preparations, as shown in Figure 4.1.1.  The drug release 
data were fitted to the Higuchi equation (47), and the drug release rate constants were 
calculated and determined to be diffusion-controlled processes (106). The drug 
release rate constant decreased from 32.8% h-1/2 to 28.1% h-1/2 when the TEC level 
increased from 4% to 7% in the directly compressed tablet formulation. A decrease in 
the rate constant from 30.8% h-1/2 to 27.9% h-1/2 was found when the TEC level 
increased from 4% to 7% in compacts containing granules prepared by the high shear 
hot-melt process. The decrease in the drug release rate constant was due to the 
presence of TEC in the interstices of the polymer, to increase the binding of the drug 
to the polymer, thus facilitating the formation of a continuous matrix structure which 
would decrease the diffusivity of the drug from the system.  The addition of TEC 
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further enhanced drug and polymer binding during thermal processing and, as a 
result, drug release rates from tablets formulated as a dry powder blend were faster 
than drug release rates from compressed tablets prepared from high shear hot-melt 
granules having 4% of TEC. 
The influence of TEC levels on the dissolution release rate of CPM from hot-
melt extruded tablets is seen in Figure 4.1.2.  The drug release rate constant was 
calculated to be 11.7% h-1/2 for tablets containing no TEC.  When 4% and 7% TEC 
were incorporated into the powder blend formulation, the release rate constants for 
the hot-melt extruded tablets containing Eudragit RS PO and 10% CPM were 
increased to 13.8% h-1/2 and 18.6% h-1/2, respectively.  CPM drug release rates 
increased with increasing levels of TEC in the hot-melt extruded tablets, whereas in 
directly compressed tablets or tablets prepared from high shear hot-melt granules, a 
decrease in the drug release rate was seen.  The high temperature and pressure of the 
hot-melt process converted the materials into a homogenous structure. For the directly 
compressed tablets and those prepared from the hot-melt granules, porous structures 
were formed.  The TEC functioned to enhance the formation of a continuous matrix 
structure in the directly compressed tablet compact. The plasticizer also enhanced the 
adhesion of polymer particles in the granules prepared by the hot-melt granulation 
process. The water-soluble plasticizer, diffused from the hot-melt extruded tablets 
into the dissolution media, enhancing drug release as a result of channel formation in 
the tablet.  This hypothesis was confirmed by determining the amount of TEC 
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released from the hot-melt extruded tablets during the dissolution study, and these 
results appear in Figure 4.1.3.  The release of TEC from the hot-melt extruded tablets 
also followed the Higuchi diffusion model. TEC was completely released after 24 
hours for the tablets containing 4% and 7% TEC. The diffusion of TEC into aqueous 
media from cast films prepared from aqueous colloidal polymer dispersions had 
previously been reported by Bodmeier and Paeratakul (107).  
4.1.1.2. Influence of CPM concentration on drug release 
The influence of CPM levels on the dissolution properties of tablets prepared 
by hot-melt extrusion is demonstrated in Figure 4.1.4.  Drug release rates increased 
with increasing amounts of CPM in the formulation.  When 6, 10 and 14% CPM was 
incorporated into the extruded formulation, the drug release rates were calculated to 
be 9.11% h-1/2, 13.8% h-1/2, and 20.0% h-1/2, respectively.  Higher level of CPM 
corresponding to lower level of the polymer in the tablet, resulted in an increase in the 
drug release rate. As more drug is released from the tablet, more channels are 
produced, contributing to faster drug release rates.  In addition, higher drug levels in 
the extruded tablet formulation produced a higher drug concentration gradient 
between the tablet and the dissolution medium. According to Fick’s first law, the 
mass flux of a component per unit cross sectional area perpendicular to the direction 
of diffusion is proportional to its concentration gradient (108), thus drug release rate 
was increased. 
The influence of CPM levels on the dissolution profiles of CPM tablets 
prepared from the granules of the hot-melt extrudates was also investigated. 
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Compared with the results in Figure 4.1.4, drug release rates were faster from tablets 
prepared with hot-melt extruded granules than from tablets compressed with dry 
powder blends (Figure 4.1.5).  Granulation of brittle hot-melt extrudates increased 
drug release after compression, due to the brittle nature of the polymer and the 
formation of internal cracks within the granules during the compaction process.  The 
granules having poor cohesive properties resulted in soft tablets with large voids 
between the granules as observed by SEM.  Drug was released rapidly through both 
the voids between the granules and the cracks within the granules.  
In contrast, drug release from tablets prepared with granules made by the hot-
melt granulation method, as seen in Figure 4.1.6, was slower than from tablets 
prepared by hot-melt extruded granules, as in Figure 4.1.5.  The high shear hot-melt 
granules were more porous than the granules prepared from hot-melt extruded tablets, 
which contributed to the good adhesion properties of the granules prepared by high 
shear hot-melt granulation, resulting in harder tablets.  Drug release rate from these 
tablets increased with increasing CPM concentration in the tablets.  
 
4.1.2. Plasticization efficiency 
The temperature and heat capacity calibration for MDSC was carried out 
utilizing Indium as the standard prior to sample analysis (100, 101, 109). The glass 
transition temperature of Eudragit RS PO was determined to be 67.4 °C using 
MDSC. A value of 61.5°C determined by DSC using a scanning rate of 10°C/min has 
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been reported by other investigators (110). The difference between the two Tg values 
was possibly due to the different methodologies used to experimentally determine this 
property. The data in Figure 4.1.7 demonstrate that the glass transition temperatures 
of blends of Eudragit RS PO and TEC decreased as a function of the percentage of 
TEC added to the formulations. Plasticizer efficiency is a function of the Tg of the 
plasticized polymer. A linear relationship between glass transition temperature and 
percent TEC in Eudragit RS PO was observed within the TEC concentration range 
of 0% to 12%. The glass transition temperature decreased 2.70°C for each percentage 
of TEC present in the polymer. Above 12% TEC in the Eudragit RS PO, the 
polymer agglomerated and could not be processed. A single glass transition 
temperature was observed for the mixtures of Eudragit RS PO and TEC, indicating 
miscibility between the two materials. 
As shown in Figure 4.1.7, the glass transition temperature of the acrylic 
polymer decreased as the concentration of CPM in the sample increased. A single 
glass transition temperature was also observed for the blends of Eudragit RS PO and 
CPM, indicating miscibility. The glass transition temperature decreased 
approximately 1.31°C for each percentage of CPM in Eudragit RS PO. These results 
indicated that the plasticization efficiency of CPM was approximately half that of the 
TEC. Both CPM and TEC exhibited a plasticization effect on Eudragit RS PO, 
suggesting that lower processing temperatures can be used during hot-melt extrusion 
of a powder blend containing these materials.  
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4.1.3. Morphology studies on granules following thermal processing 
The surface morphologies of drug and polymer physical blend as well as 
granules formed by the hot-melt processes are displayed in Figure 4.1.8. A SEM of a 
physical mixture of CPM and Eudragit RS PO in Figure 4.1.8 (A) shows that 
particles of CPM were adsorbed on the surface of Eudragit RS PO particles. When 
4% TEC was incorporated into the physical mixture, CPM particles adhered to the 
swollen surface of the Eudragit RS PO as shown in Figure 4.1.8 (B). The binding of 
the CPM to the acrylic polymer contributes to the decrease in drug dissolution rate as 
the TEC concentration in the directly compressed tablet formulation was increased. 
Figures 4.1.8 (C) and (D) show the SEM photographs at two magnifications of 
granules containing TEC plasticized CPM and Eudragit RS PO blends prepared by a 
high shear hot-melt granulation process. The lower magnification photograph (C) 
shows a typical porous granule formed after high shear hot-melt granulation. At 
higher magnification (D), the porous structure of granules formed from the fusing of 
drug and polymer particles following thermal processing is shown. Figures 4.1.8 (E) 
and (F) show the SEM photographs of hot-melt extruded granules of TEC plasticized 
CPM and Eudragit RS PO powder blends at two magnifications. These two 
photographs display a fused granule containing drug and polymer following hot-melt 
extrusion. These SEMs suggest a homogeneous distribution of the CPM in the acrylic 
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polymer and demonstrate that hot-melt extrusion technology is a thermal processing 
method that can be employed to prepare CPM-Eudragit RS PO solid solutions. 
It can be concluded from these studies, that controlled release matrix tablets 
containing CPM and Eudragit RS PO were successfully prepared using hot-melt 
extrusion and high shear hot-melt granulation techniques.  The effects of TEC levels 
on drug release rates were dependent on the thermal processing method used to 
prepare the solid composite.  As TEC levels increased, the drug release rates 
decreased for tablets prepared by either direct compression or from granules made by 
high shear hot-melt granulation.  In contrast, drug release rates increased with 
increasing TEC levels for the hot-melt extruded tablets.  The CPM content in the 
tablets influenced the drug release rates from tablet formulations, resulting in an 
increased drug release rate with increasing amounts of CPM irrespective of 
preparation method.  Granules prepared via high shear hot-melt granulation formed a 
porous discontinuous matrix structure, thus resulting in faster drug release rates.  In 
comparison, CPM was homogenously dispersed in the hot-melt extruded tablets 
resulting in a slower and more controlled release of drug.  The acrylic polymer was 
plasticized in situ by both the CPM and the TEC during thermal processing, and the 
plasticization efficiency of TEC was shown to be twice that of CPM.  The influence 
of both CPM and TEC levels on the drug release rate from these polymeric drug 
delivery systems was shown to be a function of whether the granules or tablets were 
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formed by either hot-melt granulation or hot-melt extrusion, as well as the 
plasticization effects of both TEC and CPM on the acrylic polymer. 
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4.2. Influence of Thermal Processing on the Properties of 
Chlorpheniramine Maleate Tablets Containing an Acrylic Polymer 
 
Polymer based drug delivery systems have received considerable attention in 
the scientific literature since polymeric carriers can be used to deliver a wide variety 
of drugs at a controlled rate in the gastrointestinal tract (111-114). Polymer based 
drug delivery systems prepared by thermal processing are gaining more attention in 
the pharmaceutical field. High shear hot-melt granulation (115-119) and hot-melt 
extrusion (3, 37, 72, 73, 78) are two procedures utilizing heat that can overcome the 
disadvantages of traditional processing technologies, including stability issues 
associated with wet granulation, as well as flowability and content uniformity 
problems associated with direct compression. Furthermore, no organic solvents are 
used in hot-melt granulation and hot-melt extrusion processes (36).  
One of the greatest concerns for polymeric drug delivery systems is aging, 
which is a phenomenon that results in a change in drug release rate over time.  Curing 
or post-processing thermal treatment is often employed to decrease the aging effect. 
Curing at temperatures above the glass transition temperature for a film coated pellet 
or tablet significantly enhances film formation by ensuring complete coalescence of 
the polymeric particles. Curing has been shown to reduce the permeability of an 
Eudragit RS 30D polymeric film and to decrease the drug release rate constant of 
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theophylline (85). It was also reported that post-processing thermal treatment of 
tablets containing a pseudolatex dispersion of poly(DL-lactic acid) (PLA) at 
temperatures above the Tg of the polymer significantly retarded the drug release rate 
constant from the matrix tablets (120).  
In the current study, chlorpheniramine maleate (CPM) tablets containing 
Eudragit RS PO were prepared by direct compression, high shear hot-melt 
granulation, and hot-melt extrusion and the effects of thermal processing and post-
processing thermal treatment on drug release were determined. In addition, the 
thermal stability of the materials used in the formulation and the crystallinity of CPM 
following thermal processing were investigated. 
 
4.2.1. Influence of thermal treatment on the dissolution profiles of CPM tablets 
The influence of post-processing thermal treatment on the dissolution 
properties of CPM from tablets prepared by direct compression of a dry powder blend 
of Eudragit RS PO and CPM (10%, w/w) is shown in Figure 4.2.1. By fitting drug 
release profiles to the Higuchi equation (47, 106), the drug release rate constant was 
calculated and the results suggested that the mechanism of drug release from these 
tablets occurred by a diffusion-controlled process. The CPM direct compression 
tablets containing Eudragit RS PO released more than 80% of the model drug within 
2 hours. The drug release rate constants decreased dramatically when the tablets were 
stored at 60ºC, a temperature slightly above the glass transition temperature of the 
 87
tablet components (55.5ºC).  By calculating the similarity factor f2 value for the drug 
release profiles, before thermal treatment and post-processing thermal treatment for 
24 hours, the f2 value was less than 50.  These dissolution profiles cannot be 
considered similar indicating that post-processing thermal treatment for 24 hours 
significantly decreased the drug release rate for the directly compressed tablets 
containing no TEC. 
Omelczuk and McGinity (120) had previously reported that post-processing 
thermal treatment of tablets containing a pseudolatex of PLA significantly retarded 
the release of theophylline from matrix tablets. The retardation in theophylline release 
was attributed to increased tablet hardness due to increased bonding between 
granules. Generally, amorphous solids are not in a stable thermodynamic equilibrium 
at temperatures below their glass transition temperature. These materials tend to 
undergo slow processes to establish equilibrium indicating that even below the Tg, 
molecular mobility is not zero (121). This contributes to the aging phenomenon that 
occurs in polymeric drug delivery systems. This gradual approach to equilibrium 
affects many properties of the tablet, including the dissolution rate and the 
mechanical properties. The influence of thermal effects on the drug release profiles 
from polymeric dosage forms can be explained by the free-volume theory, since the 
transport of materials in a closely packed system depends primarily on the degree of 
the entanglement, or the free volume of the system (121). The free volume of an 
amorphous material is the volume not occupied by the molecules making up the 
material (40). Post-processing thermal treatment of the tablets will increase the degree 
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of the entanglement of tablet ingredients, and decrease the free volume of the system 
to cause a decrease in permeability of the polymer.  
The dissolution profiles of tablets that contained 4% (w/w) TEC in the 
Eudragit RS PO and 10% (w/w) CPM blend are shown in Figure 4.2.2. The addition 
of the plasticizer enhances the Brownian motion of the polymer segments and 
weakens the interaction between chains, thus increasing the interchain distance (122). 
The presence of the plasticizer enhances the drug and polymer intermolecular 
entanglements and resulted in a decrease in the drug release rate as shown in Figure 
4.2.2. Thermal treatment of the tablets above the glass transition temperature of the 
plasticized polymer enhanced intermolecular binding and entanglement between drug 
and polymer molecules, thus decreasing the diffusivity of the drug from the matrix 
tablet. This effect was enhanced as the time of post-processing thermal treatment time 
was increased. After 24 hours of storage at 60ºC, the drug release rate constant was 
reduced from 36.2%h-1/2 to 30.0%h-1/2. Dissolution profile comparison also 
demonstrated that post-processing thermal treatment decreased the drug release rate 
significantly for the directly compressed tablets containing 4% TEC. 
Previous research has demonstrated that TEC can leach from the CPM - 
Eudragit RS PO hot-melt extrudates, resulting in an increase in the drug release rate 
from these extrudates (123). However, for directly compressed tablets, the influence 
of TEC on the entanglement of CPM in the Eudragit RS PO system was more 
dramatic than the effect of the leaching of TEC, since the drug release rate constant of 
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the CPM from directly compressed tablets decreased from 36.2%h-1/2 to 32.4%h-1/2 
due to the inclusion of 4% TEC. Thermal treatment of the tablets containing 4% TEC 
at 60ºC for 24 hours further increased the entanglement of CPM in the Eudragit RS 
PO system, and decreased the drug release rate constant to 31.3%h-1/2. 
Eudragit RS PO is a copolymer of acrylic and methacrylic esters with a low 
content of quaternary ammonium groups(124). Since it is a thermoplastic material, it 
will soften and become pliable when heated above its glass transition temperature. 
When the granules prepared by high shear hot-melt granulation and hot-melt 
extrudates of Eudragit RS PO were cooled, the granules and extrudates solidified 
and retained their shape. For compressed tablets composed of 4% TEC, 10% CPM 
and Eudragit RS PO granules prepared by high shear hot-melt granulation, the drug 
release rate constant was 30.8%h-1/2 as shown in Figure 4.2.3. The drug release rate 
constant was calculated to be 30.8%h-1/2. This is lower than the directly compressed 
tablets rate constant, 32.4%h-1/2. The drug release rate decreased since the high shear 
hot-melt granulation process further enhanced Eudragit RS PO intermolecular 
entanglement inside the granules.  
Figure 4.2.3 shows the effect of post-processing thermal treatment on the 
dissolution profiles of CPM tablets prepared by high shear hot-melt granulation. Drug 
release rate constants decreased from 30.8%h-1/2 to 26.9%h-1/2 following 24 hours of 
thermal treatment, which represents a reduction of 12.6% from the tablets prior to 
storage at 60°C.  
 90
Powders processed by hot-melt extrusion are subjected not only to elevated 
processing temperatures but also to high pressure. Thus, the free volume of the 
system is reduced, which further retards molecular mobility (84). The drug release 
rate constant was decreased dramatically from 30.8%h-1/2 to 13.8%hr1/2 after granules 
composed of 4% TEC, 10% CPM and Eudragit RS PO were prepared by hot-melt 
extrusion, when compared to tablets compressed from the granules processed by high 
shear hot-melt granulation. Hot-melt extrusion process had already decreased the free 
volume of the polymeric drug delivery system to a greater extent than direct 
compression and high shear hot-melt granulation. 
The profiles in Figure 4.2.4 demonstrate the influence of post-processing 
thermal treatment on the dissolution properties of CPM from hot-melt extruded 
tablets. Post-processing thermal treatment exerted a minimal influence on the drug 
release rate constant of tablets prepared by hot-melt extrusion and after 24 hours 
curing at 60°C, the drug release rate constant decreased from 13.8%hr1/2 to 
12.8%hr1/2. Hot-melt extrusion requires high temperature and pressure to process the 
powder blend into the extruded tablets. Thus, curing had minimal effects on 
enhancing drug and polymer entanglement and decreasing the polymer free volume. 
The results of this study indicated that the matrix systems prepared by hot-melt 
extrusion exhibited a slower drug release rate constant and post-process curing at 
elevated temperature had little effect on drug release. These findings suggest that 
tablets prepared by hot-melt extrusion will exhibit less aging effects during storage.  
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4.2.2. Thermal stability studies of CPM, Eudragit RS PO and TEC 
Thermal events, including melt crystallization and glass transition, do not 
cause a change in the mass of the sample, while other thermal changes, such as 
decomposition, sublimation, reduction, and vaporization are accompanied by mass 
changes (125). These changes are related to the thermal stability of the material. The 
thermogravimetric profiles of CPM, Eudragit RS PO and TEC in Figure 4.2.5 
demonstrate the change in mass of the samples as a function of temperature. For 
methyl methacrylate copolymers, previous research has shown that scission of 
polymer chains at elevated temperatures results in a monomeric product (126). The 
depolymerization of poly(methyl methacrylate) is a free-radical process that is 
initiated from the ends of the chain. Each initiated chain unzips rapidly to yield 
monomer formation. Thus, at any instant the system contains only unreacted polymer 
and monomer (127). The USP requires the determination of the content of the 
following monomers: methacrylic acid and either methyl methacrylate or ethyl 
acrylate (93). The total amount of the monomers cannot be more than 0.3%. The 
boiling point of methyl acrylate at 608mmHg is 70°C, which is an indication of the 
volatility of the monomer. As shown in Figure 4.2.5, the remaining weight percentage 
of Eudragit RS PO at the temperature higher than 450ºC was zero, which is further 
evidence for the volatility of the monomer. As monomers are the sole volatile 
decomposition products of the methacrylic copolymer, determination of the change in 
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weight of the polymer is a precise indication of the thermal stability of the polymer. 
In this study, all materials were stable up to 160ºC. When the temperature was 
increased to 200ºC, the TEC either volatilized or degraded and the weight percentage 
decreased dramatically. When the temperature reached 260ºC, no TEC remained in 
the analyzed sample. The CPM began to decompose at about 180ºC, and the weight 
percentage decreased very rapidly to about 20% of its initial weight. Eudragit RS 
PO was more stable and did not begin to decompose until heated to 330ºC.  
The thermal stability of CPM, Eudragit RS PO and TEC was investigated at 
a temperature close to the thermal processing temperature for hot-melt extrusion.  
Dynamic thermal stability studies were conducted and the mass change of the 
samples as a function of time in the isothermal mode was measured. Figure 4.2.6 
illustrates the dynamic thermal stability of CPM, Eudragit RS PO and TEC held at 
120°C for 60 minutes. There was no change in mass of CPM and Eudragit RS PO at 
120ºC for one hour. When processed by hot-melt extrusion, the procedure would hold 
the composite blend of ingredients at 115°C for less than 3 minutes. TEC has a higher 
tendency to evaporate or decompose than CPM and Eudragit RS PO at 120°C. 
These findings suggest that a short processing time or a low processing temperature 
would minimize the evaporation of the TEC. 
For the hot-melt extrusion of the Eudragit RS PO itself, the die temperature 
should be above 160°C to make the polymer soft enough to be processed. The 
dynamic thermal stability profiles of CPM, Eudragit RS PO and TEC held constant 
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at 160°C for 60 minutes are shown in Figure 4.2.7. A linear decrease in the weight 
percentage remaining as a function of time was found, with the acrylic polymer being 
the most stable. This study revealed that if a processing temperature of 160°C and a 
processing time of 60 minutes were employed for hot-melt extrusion, this would be 
detrimental for materials in the formulation. However, for the hot-melt extrusion 
process, only 2 to 3 minutes are required for the materials to pass through the 
extruder. In addition, the presence of TEC as a plasticizer in the powder blend will 
reduce the processing temperatures and stabilize components in the formulation. 
 
4.2.3. Plasticization compatibility 
The X-ray diffraction patterns of CPM, Eudragit RS PO, the physical 
mixture, high-shear hot-melt granules and hot-melt extruded granules of 14%CPM 
and Eudragit RS PO are shown in Figure 4.2.8. The CPM exhibited two sharp peaks 
(2θ=19.35, 2θ=20.30) indicating a crystalline structure, while the pure Eudragit RS 
PO polymer was shown to be an amorphous material due to the absence of complete 
steroregularity and the presence of bulky side groups in the polymer. When CPM 
(14%) was blended with Eudragit RS PO, the physical mixture exhibited the 
crystalline characteristics of the CPM. After high shear hot-melt granulation, there 
was a decrease in the peak intensity representing a decrease in crystallinity of the 
drug substance. In contrast, no crystalline peaks were observed with the hot-melt 
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extruded samples indicating that the CPM was in the amorphous state following hot-
melt extrusion.  
The concentration of drug in the hot-melt extrudates did not affect the degree 
of crystallinity, as shown in Figure 4.2.9.  As the CPM level increased from 14% to 
30%, the model drug remained in the amorphous state. These results demonstrate that 
CPM and Eudragit RS PO are miscible when up to 30% of CPM was incorporated 
into the polymer, suggesting that a solid solution was formed during hot-melt 
extrusion processing. 
It may be concluded from this study, that the drug release rate constants from 
the controlled-release matrix tablets containing CPM and Eudragit RS PO prepared 
by direct compression (DC), high shear hot-melt granulation (HMG) and hot-melt 
extrusion (HME) were 36.2%h-1/2, 30.8%h-1/2, and 13.8%h-1/2, respectively. The drug 
release rate was decreased for tablets prepared by thermal processes. The post-
processing thermal treatment of tablets at 60°C for 24 hours further decreased drug 
release rate constants to 30.0%h-1/2 (DC), 26.9%h-1/2 (HMG), and 12.8%h-1/2 (HME). 
Post-processing thermal treatment at 60°C for 24 hours had a minor influence on the 
drug release rate from tablets prepared by hot-melt extrusion due to its minimal effect 
on drug and polymer entanglement. During hot-melt extrusion, the free volume and 
the mobility of the polymer and drug mixture were reduced, thus decreasing the 
permeability of the drug from the polymer. Eudragit RS PO, CPM and TEC used in 
this investigation were thermally stable during thermal processing as illustrated by 
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thermogravimetric analysis.  Finally, the X-ray diffraction patterns following hot-melt 
extrusion demonstrated that CPM was dispersed homogeneously at a molecular level 
in Eudragit RS PO. The CPM was in the amorphous state and miscible with the 
polymer at concentrations up to 30%.  
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4.3. Influence of a Lipophilic Thermal Lubricant on the Processing 
Conditions and Drug Release Properties of Chlorpheniramine 
Maleate Tablets Prepared by Hot-melt Extrusion 
 
Hot-melt extrusion has recently been demonstrated to be a viable method to 
prepare granules, sustained release tablets (37) and transdermal drug delivery systems 
(42). However, due to the thermal stress and shear stress involved in this thermal 
processing, several concerns should be paid on the processibility, thermal and 
chemical stability of the ingredients in the formulation in order to achieve the 
processable and stable pharmaceutical products.  
The hot-melt extruder is typically composed of four heating zones: feed zone, 
compression zone, metering zone, and die (55). Temperatures at different zones are 
controlled by several thermocouples in the barrel. The materials melt at elevated 
temperatures and the molten mass is continuously pumped through the die attached at 
the end of the barrel. The melt viscosity of a polymer, a measure of the frictional 
forces between the molecules in a liquid, is an important parameter for the indication 
of processibility.  
When molecular weights exceed a critical point (between about 10,000 and 
40,000), higher molecular weight polymers are more viscous and difficult to extrude. 
Since a higher molecular weight polymer macromolecule is linked to its neighbors at 
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many points (89), the entanglements of the chains with one another becomes 
important and the viscosity at low rates of shear depends upon weight average 
molecular weight to a power equal to about 3.4 or 3.5 (46, 88). For polymethyl 
methacrylate, the critical molecular weight is 10,400 (46). This would seem to make 
the hot-melt extrusion of the Eudragit RS PO, a copolymer of acrylic and 
methacrylic esters with the molecular weight of 150,000, a challenge for preparing 
pharmaceutical delivery systems by this thermal processing. 
In addition to the molecular weight and structure of the polymer, the 
rheological properties of polymer melt also depend upon processing temperature, 
pressure, the rate of shear, as well as upon the incorporation of various additives (46), 
which may provide us some solutions to solve the above problem. 
Changing temperature is an effective means of controlling melt viscosity in 
the processing operation as revealed by the Willams-Landel-Ferry equation and the 
Andrade or Arrhenius equation (86). However, two drawbacks are related to the 
increases in temperature. First, it is not economical to put in and take out thermal 
energy. Second, excessive temperatures can lead to degradation of the polymer and 
the active drug in the formulation. There is certainly an upper limit to the processing 
temperature we can use for a particular polymer and a drug which depends upon the 
degradation temperatures of the materials.  
The effect of pressure on polymer melt viscosity becomes noticeable only at 
fairly high pressure due to their relative incompressibility (86). The viscosity of 
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polymer melts is shear-rate dependent (87). Both fairly high pressure and high 
shearing rate can theoretically decrease the melt viscosity of the polymer. However, 
they are impractical in the hot-melt extrusion processing for the pharmaceutical 
application. Therefore, the use of the formulation method to improve the thermal 
processing would be more interesting to pharmaceutical scientists. 
Several plasticizers have been used in the hot-melt extrusion process to 
prepare drug delivery systems (37, 42). Plastcizers function by lowering the glass 
transition temperature of the polymer in the formulation thus facilitating thermal 
processing. Most of the pharmaceutical grade plasticizers used are liquid plasticizers. 
The shortcoming of liquid plasticizers in pharmaceutical application is that they 
cannot be used at high levels due to the difficulty of mixing the polymers with the 
liquid plasticizers. Consequently, to enhance the thermal processibility, a solid 
thermal lubricant can be added to the formulation in conjunction with the liquid 
plasticizer to lower the melt viscosity, thus preventing the need for high levels of a 
liquid plasticizer. For the application of the thermal lubricant, D. Henrist and J.P. 
Remon included the glyceryl monosterate in a starch based theophylline delivery 
system produced with a twin screw co-rotating extruder (128). However, the authors 
did not investigate the mechanism of a thermal lubricant facilitating the thermal 
processing.  
In this study glyceryl monostearate (GMS) was selected as a lipophilic 
thermal lubricant.  The melt viscosity of the formulation containing GMS was 
determined to investigate its effect on the thermal processibility. The drug release, 
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microstructure and the crystallinity of the extrudate were also evaluated to 
investigated the properties of the chlorpheniramine maleate (CPM) controlled release 
tablets containing Eudragit RS PO and GMS prepared by hot-melt extrusion. 
 
4.3.1. Thermal stability studies of CPM, Eudragit RS PO and TEC 
The thermal stability of CPM, Eudragit RS PO, GMS and TEC as 
determined by TGA is shown in Figure 4.3.1. These data indicate that with the 
exception of TEC, the remaining materials were stable at 120°C for 60 minutes. 
CPM, Eudragit RS PO and GMS were quite stable, while 10.55% of TEC 
evaporated indicating the volatile properties of TEC. However, the powder composite 
takes only 2 to 3 minutes to pass from the hopper through to the die. The loss of TEC 
during this short period of time in the hot-melt extrusion process was less than 0.5% 
as determined by the dynamic thermal study.  
 
4.3.2. Hot-melt extrusion processing parameters for Eudragit RS PO 
Eudragit RS PO is a copolymer synthesized from acrylic and methacarylic 
acid esters and contains a low level of quaternary ammonium groups. It has been used 
to prepare matrix tablets by direct compression (103), and wet granulation techniques 
(104, 105). Due to its low glass transition temperature, this acrylic polymer can be 
used to formulate controlled release tablets containing CPM by hot-melt extrusion 
(123).  
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During the hot-melt extrusion, the drive AMPS and the pre-die pressure are 
two parameters indicating the resistance of the melt materials within the extruder, as 
well as the processibility of the formulation. The drive AMPS is related to the torque 
of the screw. The torque is defined as the force of resistance on the screw to maintain 
a specific speed. The pressure gage indicates the pressure at the location of the probe, 
which is present at the end of the barrel just before the die. The pre-die pressure is 
determined by the shape of the die, the temperature of the polymer melt, the flow rate 
through the die, and the rheological properties of the polymer melt (87).  
Table 4.3.1 shows the thermal processing parameters for Eudragit RS PO. At 
a screw rotation rate of 20rpm and with temperature settings in Zone 1, Zone 2, Zone 
3, and Zone 4 being 120°C, 160°C, 180°C, and 190°C, respectively, the melt 
Eudragit RS PO cylinders can be extruded smoothly from the die as the acrylic 
polymer molecules became flexible at these temperatures. With a decrease in 
processing temperature (die) from 190°C to 150°C, the polymer molecules become 
more rigid. Therefore, the drive AMPS was increased from 2.0AMPS to 3.66AMPS, 
indicating higher power consumption and poor processability of the polymer at the 
lower processing temperature. Eudragit RS PO could not be processed when the die 
temperature was lower than 140°C due to the high resistance of the unmelted polymer 
on the extruder.  
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4.3.3. Effect of TEC on the hot-melt processing parameters 
When Eudragit RS PO was processed by hot-melt extrusion, it required a die 
temperature as high as 190°C. Lower temperatures consumed higher screw driving 
energy and also generated higher pre-die pressure. When 4% TEC was incorporated 
into the Eudragit RS PO, the acceptable processing temperature at the die was 
reduced to 150°C. With the same processing temperature setting in each of the 
heating zoon, the hot-melt processing parameters for TEC plasticized Eudragit RS 
PO are shown in Table 4.3.2. Without TEC in the polymer, the drive AMPS for 
Eudragit RS PO was 3.66 AMPS. When 4% or 8% TEC was incorporated into the 
Eudragit RS PO, the drive AMPS decreased to 1.92 AMPS and 1.14AMPS 
respectively. The pre-die pressures were also decreased with an increase in TEC. This 
clearly demonstrated that TEC can facilitate thermal processing, suggesting an 
improvement in the processability of the polymer with the addition of TEC.  This can 
be attributed to the fact that TEC can lower the glass transition temperature of 
Eudragit RS PO as described in a previous report (123).  This finding can also be 
explained based on melt viscosity data.  
The melt viscosity of the materials is a measure of the frictional forces 
between the molecules in a liquid and can be used to reflect the processability of the 
thermal processing and is directly related to the torque values. The toque was 
determined by using an Electronic Torque Rheometer at specific temperature settings 
and screw rotation rates. The torque is the force of resistance on the screw to maintain 
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a specific speed. The torque values of the Eudragit RS PO powder containing 
different levels of TEC were determined during thermal processing and as seen in 
Figure 4.3.2, the torque decreased with an increase in plasticizer concentration. It was 
reported that the melt viscosity of polyethylene oxide was significantly decreased 
with the addition of polyethylene glycol (37). The reduction in the torque value was 
due to a decrease in frictional shear between the powder blend and the machinery. 
Processing the powdered blend at lower temperatures will also help to stabilize both 
the active drug and other materials in the formulation.  
 
4.3.4. Effect of GMS on the hot-melt processing parameters 
The influence of glyceryl monostearate (GMS), a thermal lubricant, on hot-
melt processing parameters was also investigated and the results are shown in Table 
4.3.3 with processing variables as follows: a screw rotation rate of 20rpm and the 
temperatures in Zone 1, Zone 2, Zone 3, and Zone 4 (die) being set at 110°C, 130°C, 
140°C, and 150°C, respectively. With a melting point of 67.5°C, when GMS was 
incorporated into the Eudragit RS PO powder blend and processed at the above 
temperatures, it melted completely and resulted in decreased drive AMPS as shown in 
Table 3, demonstrating that the GMS improved thermal processibility, lowered the 
thermal processing temperatures and served as a thermal lubricant. 
The melt viscosity of the powder blend of Eudragit RS PO and GMS was 
also determined by using an Electronic Torque Rheometer as seen in Figure 4.3.3. 
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The torque values were found to decrease with an increase in GMS levels. GMS 
improved the Eudragit RS PO processibility by decreasing the melt torque values. 
This explained the observation of the GMS facilitating thermal processing.  
 
4.3.5. Miscibility studies 
The DSC profile on the top left corner of Figure 4.3.4 shows the melting 
behavior of GMS with a melting point of 67.5°C. To the right, is shown the thermal 
transition of Eudragit RS PO with a glass transition temperature of 64.33 °C. The 
two diagrams on the lower half of Figure 4.3.4 show the combination of the melt 
behavior plus a glass transition of the polymer, indicating GMS was immiscible with 
Eudragit RS PO when 8% and 16% of GMS powder were blended with Eudragit 
RS PO due to the hydrophobic properties of GMS. 
 
4.3.6. Morphology studies on the hot-melt extrudates 
Previous studies have shown that in the absence of GMS in the powder blend, 
CPM, Eudragit RS PO, and TEC were quite compatible with each other due to their 
similar solubility properties (123). GMS was immiscible with Eudragit RS PO 
following hot-melt extrusion as shown in Figure 4.3.5. The morphology of the 
granules formed by the hot-melt process and the results of the  miscibility study 
clearly showed that GMS was a thermal lubricant and not a plasticizer for the acrylic 
polymer. The inclusion of GMS in the formulation formed a coating on the polymer 
 104
during processing resulting in smoother extrudates which minimized the sticking of 
the molten polymer to the machinery, thus improving the thermal processibility. 
 
4.3.7. Dissolution studies 
Drug dissolution profiles from the hot-melt extruded tablets containing the 
thermal lubricant GMS  are shown in Figure 4.3.6. The GMS increased the drug 
release rate from tablets containing Eudragit RS PO prepared by hot-melt extrusion. 
This is due to the fact that the GMS weakened the polymeric structure of Eudragit 
RS PO and increased the drug diffusivity from the polymer. Another explanation is 
that as the GMS level in the formulation was increased less polymer was present in 
the extruded tablet. Additionally, the incorporation of GMS decreased the pre-die 
pressure and resulted in the extrudates with higher free volumes in the polymeric 
delivery systems. Therefore, release rate of CPM increased with an increase of GMS 
in the extrudates. 
 
4.3.8. Crystallinity of the hot-melt extrudates 
The X-ray diffraction patterns of CPM, GMS, Eudragit RS PO, the physical 
mixture and hot-melt extrudates of 14% CPM, 10% GMS and Eudragit RS PO are 
shown in Figure 4.3.7. CPM exhibited two sharp peaks at 2θ equal to 19.35°, and 
20.30°. Crystallinity was also seen with the GMS which exhibited two peaks at 2θ 
equal to 19.65° and 23.40°. The Eudragit RS PO polymer was shown to be an 
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amorphous material due to the absence of complete steroregularity and the presence 
of bulky side groups in the polymer. The physical mixture containing 14% CPM, 
10% GMS, and Eudragit RS PO showed a crystalline character due to the presence 
of the drug and the thermal lubricant. The hot-melt extrudates of the formulation also 
show a decreased peak intensity, indicating a decreased crystallinity of the CPM in 
the extrudates. It was reported for the indomethacin/PVP system following hot-melt 
extrusion that indomethacin was converted into the amorphous form at higher 
processing temperatures while the crystallinity of the drug was detected from the 
extrudates processed at lower temperature (77). Zhang and McGinity reported that the 
crystalline state of the theophylline was maintained in the extruded granules 
containing poly(vinyl acetate) with the extruder die temperature of 75°C (36). In 
another study, even though diphenhydramine hydrochloride and Eudragit E 100 
have the same solubility parameter which indicates possible miscibility, however, the 
crystalline drug was observed following the hot-melt extrusion due to the fact that the 
processing temperature of 80-130°C was much lower than the melting point of 
diphenhydramine hydrochloride (166-170C°) (129).  Previously, it has been found 
that CPM could form a solid solution with Eudragit RS PO at a level up to 30% of 
CPM. In the present study, the appearance of the crystallinity of CPM in the hot-melt 
extrudates may be due to the incomplete melt of the drug. CPM was partially 
transformed into an amorphous form since a lower processing temperature was used 
as the result of the incorporation of TEC and GMS. 
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In summary, Eudragit RS PO, CPM, GMS, and TEC were found to be 
thermally stable as shown by the TGA study. TEC decreased the glass transition 
temperature and the melt viscosity of Eudragit RS PO and facilitated the thermal 
processing. Both DSC and SEM studies demonstrated that GMS was not miscible 
with Eudragit RS PO. GMS facilitated the hot-melt extrusion process by decreasing 
only the melt viscosity of the Eudragit RS PO, by acting as a thermal lubricant. With 
an increase in the GMS content, the release rates of CPM from Eudragit RS PO hot-
melt extruded tablets increased.  CPM was partially in the crystalline state after hot-
melt extrusion processing with Eudragit RS PO and GMS. The incorporation of a 
thermal lubricant such as GMS into a powder blend will decrease the thermal 
processing temperatures and potentially allow more drugs and polymers to be 
processed by hot-melt extrusion.  
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4.4. Influence of Plasticizer Level on the Drug Release from 
Sustained Film Coated and Hot-melt Extruded Dosage Forms 
 
Plasticizers are materials incorporated in a polymer to increase its workability 
and flexibility(38).  Plasticizers decrease the glass transition temperature (Tg) of the 
polymer. Therefore, less energy is required for molecular bond rotation. In 
pharmaceutical applications, hot-melt extrusion and aqueous polymeric coating are 
two thermal processes with different heat intensities. Plasticizers are typically used in 
the formulation to facilitate the polymers become capable of flow at lower 
temperatures for hot-melt extrusion and to lower the minimum film formation 
temperature and enhance the polymer particle coalecence during the film coating 
process.  
In addition to the ability to enhance the thermal processing, the effect of the 
plasticizers on drug release rate is another major concern in the design of drug 
delivery systems. The influence of plasticizer level on drug release from aqueous 
polymeric film coated tablets or pellets was already investigated by several research 
groups. Wu and McGinity (45) investigated the influence of a non-traditional 
plasticizer, methylparaben, on drug release. For ibuprofen beads coated with 
Eudragit RS 30D containing methylparaben, the drug release rate decreased when 
the methylparaben levels were increased from 5% to 15%. Bodmeier et al 
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investigated the influence of a plasticizer on drug release over a wide range of the 
plasticizer level. In their studies, propranolol hydrochloride beads were coated with 
Eudragit RS 30D containing triethyl citrate (43). A U-shaped drug release profile 
was found. The release rate constant was high at low plasticizer levels, then went 
through a minimum plateau, and increased at higher plasticizer concentrations. At 
low plasticizer levels, TEC increased the coalescence or fusion of the insufficiently 
plasticized latex particles and resulted in a decreased drug release. At high levels of 
TEC, the increase in release rate constant was due to the leaching out of the water-
soluble plasticizer from the coated beads.  
Hot-melt extrusion has been recently demonstrated to be a viable method to 
prepare granules, sustained release tablets (37) and transdermal drug delivery systems 
(42). It offers many advantages over traditional processing techniques. Plasticizers 
have been used in several research studies on the hot-melt extrusion (37, 42). 
However, the influence of plasticizer level on the drug release mechanism from the 
hot-melt extrudated systems has not been explored yet. Investigation of the influence 
of the plasticizer level on drug release rate provides us another way to reveal the 
function of the plasticizer on the polymeric drug delivery system during the thermal 
preparation processing.  
The purpose of the current research was to investigate the influence of a water 
soluble plasticizer, triethyl citrate (TEC), on the drug release rate from the hot-melt 
extrudates containing acrylic polymers and model drugs with different 
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physicochemical properties.  The two highly water-soluble drugs selected included 
chlorpheniramine maleate (CPM) and diltiazem hydrochloride (DTZ). The poorly 
water-soluble drug selected was indomethacin (IDM). Aqueous film coating, a less 
heat intensive thermal process, was also employed to investigate the plasticizer level 
in the coating formulation on the drug release from diltiazem hydrochloride pellets 
coated with Eudragit RS 30D.   
 
4.4.1. Thermal stability  
 The physical stability of the materials used in the hot-melt extrusion 
formulations was determined by TGA under a nitrogen atmosphere as shown in 
Figure 4.4.1. It was indicated that there was no weight loss for diltiazem 
hydrochloride until a temperature of 230°C was reached. This result is consistent with 
the reported data by Mazzo, et al (130). Significant weight loss was observed beyond 
250°C due to the decomposition or vaporization of the DTZ, Eudragit RS PO and 
TEC. The thermal stability of CPM and IDM were determined and previously 
reported (123). 
 
4.4.2. Chemical stability of DTZ following hot-melt extrusion 
 The drug contents before and following hot-melt extrusion were determined 
by using a USP stability indicating HPLC assay method as described in Table 4.4.3. 
The drug content decreased less than 2% following processing. No degradant peaks 
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were observed in the chromatograms. Follonier, et al who processed DTZ with 
Eudragit RS PM by hot-melt extrusion at 140°C also reported that no significant 
difference in drug content between the reference and the DTZ extrudates was 
observed in samples, before and after processing (73). These results demonstrated 
that DTZ was chemically stable following hot-melt extrusion, indicating that the hot-
melt extrusion processing conditions employed in this study were acceptable for the 
preparation of DTZ hot-melt extrudates.  
 
4.4.3. Plasticization effect of DTZ on Eudragit RS PO  
In our previous research a solid-state plasticization effect by both CPM and 
IDM on Eudragit RS PO was observed. In the current study, no solid plasticization 
effect on Eudragit RS PO was seen with highly water-soluble drugs, including 
diltizem hydrochloride, propranolol hydrochloride, diclofenac sodium, and naproxen 
sodium. The absence of a solid-state plasticization effect of these drugs on Eudragit 
RS PO was due to their higher melting points; for example the melting point of DTZ 
is 214.6°C (130). Diltiazem hydrochloride was selected for further investigation due 
to its lack of plasticization effect on Eudragit RS PO as shown in Figure 4.4.2. In 
addition, good compatibility between DTZ and the aqueous colloidal dispersion, 
Eudragit RS 30D, was a further reason to select DTZ as the model drug. This 
negates the possibility of precipitation of Eudragit RS 30D polymer as flocculates 
on the surface of the DTZ beads during the coating process.  
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4.4.4. Influence of TEC concentration on drug release 
4.4.4.1. From hot-melt extrudates containing CPM 
The influence of TEC levels on the drug release from the hot-melt extrudated 
tablets containing CPM is seen in Figure 4.4.3. The drug release rate was increased 
with the increase of the TEC from the hot-melt extruded delivery system containing 
CPM and Eudragit RS PO. CPM exhibited a solid-plasticization effect on Eudragit 
RS PO and a solid solution with a continuous structure was formed following hot-
melt extrusion as reported previously (123). However, TEC was released from the 
hot-melt extrudates in the dissolution test (123). The diffusion of TEC into aqueous 
media from cast films prepared from aqueous colloidal polymer dispersions had 
previously been reported (107).  
4.4.4.2. From hot-melt extrudates containing DTZ 
Diltiazem hydrochloride is a calcium channel blocker widely used in the 
treatment of angina pectoris, supraventricular tachycardias, and hypertension (131). It 
is a highly water-soluble drug with a solubility in the range of 588mg/ml to 678mg/ml 
in the pH range of 1.0 to 5.8 (132). The influence of TEC levels on the dissolution 
rate of DTZ from the hot-melt extruded tablets containing 30% DTZ is seen in Figure 
4.4.4. The drug release rate increased with the increase of the TEC level. This finding 
is consistent with the effect of TEC level on the drug release of another highly water-
soluble drug, CPM, from the hot-melt extrudates as reported above. Even though 
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DTZ did not exhibit the plasticization effect on Eudragit RS PO, a continuous 
polymeric structure was formed following thermal extrusion processing.  
The data in Figure 4.4.4 also reveals that a drug release burst effect from the 
hot-melt extrudates was eliminated as the result of the thermal processing. It was 
reported that for this highly water-soluble drug, DTZ was distributed in the coating 
polymer matrix when dichloromethane was used as the solvent and Eudragit RS 100 
as the coating material to prepare microparticles by the spray-drying technique. 
Microcapsules were formed when using toluene. It was reported that the initial 
release from microcapsules was faster due to the presence of some uncoated drug 
crystals (133).  
4.4.4.3. From Eudragit RS 30D coated beads containing DTZ 
It is generally accepted that the film-forming process occurs in three stages: 
(I) evaporation of the water until the particles reach close-packing; (II) formation of 
particle contacts and deformation of that latex particles as the particle volume fraction 
goes above that of a close-packed structure; (III) gradual coalescence by 
interdiffusion of polymer molecules between latex particles (134). Following the 
aqueous polymeric coating process, without any curing on the coated pellets, the film 
formed has a higher permeability due to incomplete coalescence. As the film was 
cured, the permeability approached a minimal value and remained relatively 
unchanged over a period of time (135). The cured DTZ pellets were used for the 
dissolution studies. Figure 4.4.5 shows the influence of TEC level in the Eudragit 
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RS 30D coating layer on the dissolution rate of DTZ from coated pellets with a 15% 
polymer weight gain. The drug release rate decreased with the increase of the TEC 
level. Several authors have observed the same drug release phenomena for the coated 
beads (45, 94, 136). The addition of a plasticizer facilitates the polymer particle 
coalescence. The formation of a continuous polymeric structure decreased the 
permeability of the film. 
4.4.4.4. From hot-melt extrudates containing IDM 
The influence of TEC level on the drug release from the hot-melt extrudated 
granules (20-40 mesh) containing a poorly water-soluble drug, IDM, and Eudragit 
RD 100 is seen in Figure 4.4.6. The dissolution profiles comparison was carried out 
using a model independent method (56). By calculating the similarity factor f2 values, 
the f2 values between the formulations were greater than 50, which means that these 
dissolution profiles can be considered similar. The addition of TEC in the hot-melt 
extrudates formulation did not influence the drug release for a poorly-water soluble 
drug. This could be contributed to the low solubility of the drug and the drug release 
rate was controlled by intraparticle diffusion. 
 
4.4.5. Microstructures of Hot-melt extrudates and surface morphology of coated 
beads 
4.4.5.1. Hot-melt extrudates 
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The surface morphologies of the hot-melt extrudates containing 30% DTZ, 
66% Eudragit RS PO and 4% TEC are displayed in Figure 4.4.7. This SEM picture 
showed that a continuous polymeric structure was formed following hot-melt thermal 
processing, even though the DTZ was not dispersed homogeneously at the molecular 
level in the acrylic polymer. This will be further confirmed by the X-ray diffraction 
studies. 
4.4.5.2. Coated beads 
The surface morphologies of the Eudragit RS 30D coated DTZ beads 
containing different levels of TEC in the coating layer are displayed in Figure 4.4.8. 
With an increase in the amount of TEC incorporated in the formulations, the surface 
morphology of the coated beads became smoother as the higher levels of TEC 
contributed to a more complete coalesence of the polymeric particles in the Eudragit 
RS 30D film coatings.  
 
4.4.6. Crystallinity follwing hot-melt extrusion 
The X-ray diffraction patterns of DTZ, Eudragit RS PO, the physical 
mixture, and hot-melt extrudates containing 30% DTZ and Eudragit RS PO are 
shown in Figure 4.4.9. The DTZ exhibited several sharp peaks in the 2θ range from 
10° to 28° indicating a crystalline structure, while the pure polymer Eudragit RS PO 
was shown to be an amorphous material. When DTZ (30%) was blended with 
Eudragit RS PO, the physical mixture exhibited the crystalline characteristics of the 
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DTZ. Crystalline peaks were also observed with the hot-melt extruded samples 
indicating that the DTZ was in the crystalline state following hot-melt extrusion. The 
crystallinity of DTZ following hot-melt extrusion is the result of the high melting 
point of the DTZ and the immiscibility of the drug with the polymer as revealed by 
the DSC data. It was reported by Zhang and McGinity (36) that the crystalline state of 
theophylline was maintained in the extruded granules containing poly(vinyl acetate) 
with an extruder die temperature of 75°C. Even though diphenhydramine 
hydrochloride and Eudragit E 100 have the same solubility parameter, which signals 
the possible miscibility of the two materials, the crystalline drug was observed 
following hot-melt extrusion in a processing temperature range of 80-130°C which 
was lower than the melting point of diphenhydramine hydrochloride (166-170C°) 
(129). 
 
In conclusion, DTZ and the excipient components of the extruded tablets were 
thermally and chemically stable at thermal processing temperatures of 90°C to 140°C, 
as shown by TGA and HPLC. No plasticization effect of DTZ on Eudragit RS was 
observed. The influences of TEC levels on drug release rates were dependent on the 
thermal processing methods used to prepare the solid composite. An increase in the 
TEC level resulted in an increase in the DTZ or CPM release rate from the extruded 
tablets, while the drug release rate from the coated DTZ pellets decreased when the 
TEC level in the coating formulation was increased. DTZ was in the crystalline state 
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following thermal processing. Different levels of TEC in the IDM hot-melt extrudated 
granules produced a similar drug release profile. This could be due to the lower 
solubility of IDM and the drug release rate was controlled by intraparticle diffusion.  
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4.5. Properties of Hot-melt Extrudated Solid Solutions Containing 
Acrylic Polymers and a Poorly Water-Soluble Drug 
 
There are many factors influencing the bioavailability of a pharmaceutical 
product.  Among these factors, the two most important physicochemical properties of 
a drug are its solubility and permeability.  If a drug substance has an aqueous 
solubility of less than 10mg/ml in solution at 37°C over a pH range of 1 to 7, 
dissolution is the rate-limiting step in the process of drug absorption (8).  Therefore, a 
potential bioavailability problem may occur and methods for improving drug 
solubility should be explored.  Enhancing the oral bioavailability of poorly water-
soluble drugs is one of the most challenging issues in the drug development, and 
several techniques such as micronization and salt formation, have been investigated. 
These methods have limitations due to the agglomeration of the micronized powder 
or the reconversion of salts into aggregates of their respective acid or base forms.  
The first breakthrough in this area was the investigation of a solid dispersion 
conducted by Sekiguchi and Obi in 1961 (9).  It was demonstrated that without those 
limitations mentioned above a eutectic mixture of sulfathiazole and urea had a much 
higher dissolution rate leading to better absorption following oral administration as 
compared to sulfathiazole administered alone.   
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Even though solid dispersion technology provides many advantages over the 
traditional techniques (11, 137), only two products, a griseofulvin-in-poly(ethylene 
glycol) solid dispersion (Gris-PEG, Novartis) and a nabilone-in-povidone solid 
dispersion (Cesamet, Lilly) were marketed due to the existence of the following 
problems: (a) the melt or solvent preparation methods, (b) the reproducibility of the 
physicochemical properties, (c) formulation into dosage forms, (d) the scale-up of 
manufacturing processes, and (e) the physical and chemical stability of drug in the 
solid dispersions (12).  In recent years, solid dispersion technology was gained 
recognition due to the application of hot-melt extrusion in the pharmaceutical field 
(13).  An important advantage of the hot-melt extrusion is that the drug/carrier 
mixture is subjected to an elevated temperature for only a few minutes, which allows 
both the drug and the carrier to be both thermally and chemically stable.  Due to the 
simplicity of manufacturing and scale up processes, the physicochemical properties of 
solid dispersions are not expected to change significantly during the scale-up.  For 
this reason, the application of hot-melt extrusion will grow rapidly in the preparation 
of solid dispersions. 
To enhance the bioavailability of poorly water-soluble drugs, highly water-
soluble carriers were used to prepare the solid dispersions.  When a mixture 
consisting of a poorly water-soluble drug and an inert highly water-soluble carrier is 
dissolved in an aqueous medium, the drug release mechanism causes the carrier to 
dissolve rapidly, releasing very fine crystals of the drug.  The large surface area of the 
resulting suspension should result in an enhanced dissolution rate and thereby 
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improve bioavailability.  For the purpose of preparing a sustained solid dispersion 
delivery system containing the poorly water-soluble drugs, the same hot-melt 
extrusion process can be employed.  The only difference is the selection of polymers 
with suitable permeability.  Solid solutions can improve the drug solubility to the 
greatest extent.  In order to prepare solid solutions, an important prerequisite is the 
miscibility of the drug and the carrier in the molten state.  When there are miscibility 
problems, this usually leads to a product that is not molecularly dispersed.   
Furosemide is a diuretic and antihypertensive drug that is practically insoluble 
in water.  Controlled drug release tablets were prepared by compressing the granules 
of solid dispersions containing furosemide and Eudragit RS/RL PO made by the 
solvent (methanol) method (29). Flurbiprofen is a non-steroidal anti-inflammatory 
drug with a slight water solubility (30mg/ml in water at 37°C). Solid dispersion 
granules containing flurbiprofen (FP) and poly(ethylene oxide) (PEO) or HPC were 
prepared by solvent (ethanol) method (14).  The release rate of the drug from the FP-
PEO system was significantly larger than that from FP powder and the FP-HPC 
system. The dissolution property of the polymer base greatly affected the release of 
FP from the solid dispersions. In the FP-PEO system, the release rate increased with 
the increasing percent of PEO. 
Several acrylic polymers were evaluated to formulate the sustained 
indomethacin solid solutions.  Eudragit RS PO / RL PO are copolymers synthesized 
from acrylic and methacarylic acid esters which contain a low level of quaternary 
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ammonium groups.  The Eudragit RL polymer contains a greater molar ratio of 
these ionizable groups, which causes it to be more readily permeable than the 
Eudragit RS PO.  The Eudragit RD 100 is a new product from Röhm America.  It 
is a powder combination of 91% of Eudragit RL PO and 9% of sodium 
carboxymethyl-cellulose.  This material is currently used for film coating immediate 
release dosage forms.  The Eudragit RD 100 was selected in this study since it 
exhibits higher permeability compared to the Eudragit RS PO/ RL PO.   
Several researchers have reported that hot-melt extrusion can be used to 
enhance the bioavailability of poorly water-soluble drugs (77), but the development 
of the controlled release dosage forms for poorly water-soluble drugs which avoid the 
risk of the burst effect has not been investigated using this thermal processing.  In this 
study, indomethacin, a poorly water-soluble drug (solubility in water is 4.0-8.8 
µg/ml) (138) was selected and controlled release drug delivery systems containing 
several acrylic polymers were prepared by hot-melt extrusion.  The thermal and 
chemical stability of the materials used in the formulation was evaluated through the 
preformulation, and formulation studies were conducted to reveal the controlled drug 
release mechanisms.  
 
4.5.1. Particle size, true density, melting point and glass transition temperature 
 The particle size of indomethacin, Eudragit RL PO, and Eudragit RD 100 
was determined by using a Zeta Potential Analyzer with a BIC particle sizing 
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software and is shown in Table 4.5.1.  The average effective diameters for these three 
materials as received were 13.98µm, 40.96µm, and 43.11µm respectively, which 
represents the fine particles of these materials.   
 The true density of indomethacin, Eudragit RL PO, and Eudragit RD 100 
was determined by using a helium pycnometer (139).  The average true densities for 
these three materials as seen in Table 4.5.2 were 1.3756g/cm3, 1.1887g/cm3, and 
1.2094g/cm3, respectively.   
Due to its different molecular arrangements and/or conformations, 
indomethacin has been shown to exhibit four polymorphs with different melting 
points (140).  The melting point of indomethacin for Form I was 160-161.5°C, for 
Form II, III, and IV the melting points were reported to be 154.5-155.5°C, 148°C, and 
134°C, respectively (138). The melting point of the indomethacin powder as received 
was determined to be 162.46°C using DSC at a heating rate of 10°C/min from –10 to 
180°C as seen in Figure 4.5.1.  This result showed that indomethacin was in the 
crystal Form I prior to hot-melt extrusion. Form I is the most stable polymorph and 
has the lowest solubility.  The energy required for a molecule to escape from a crystal 
is much greater than the energy required to escape from an amorphous powder, which 
explains why the crystal form of a compound is always less soluble than the 
corresponding amorphous form (141).  The amorphous form was formed as a result of 
the quenching process in the first run. A glass transition phenomenon was observed in 
the second run of the indomethacin using DSC and the glass transition temperature 
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was found to be 47.77°C, which is close to the values of 45°C (58), and 50°C, 
reported by  Zografi et al (19).  
 
4.5.2. Plasticization effect of indomethacin on Eudragit RL PO 
The solid-state plasticization effect of indomethacin on Eudragit RL PO was 
determined by DSC at a heating rate of 10°C/min from –10 to 180°C.  The DSC 
profile of the mixture of indomethacin and Eudragit RL PO of the first run showed 
an endothermal peak of 157.8°C due to the melting behavior of the indomethacin.  
During the first run, samples underwent both heating and cooling processes, so their 
previous history was erased.  In the second run, the glass transition temperatures (Tg) 
of the mixtures of Eudragit RL PO and indomethacin were determined as shown in 
Figure 4.5.2.  A slight decrease in the Tg was seen using 40% indomethacin in the 
Eudragit RL PO mixture.  Since glass transition temperatures for pharmaceuticals 
are generally found to be about two thirds that of the melting temperatures (142), the 
melting point of indomethacin is 162.5°C and chlorpheniramine maleate (130-135°C) 
(143), it was not surprising to see that the solid-state plasticization effect was weaker 
for the mixture containing indomethacin in Eudragit RL PO compared to 
chlorpheniramine maleate in Eudragit RS PO.  When a compound is miscible with 
the polymer in the molten state, the lower the melting point, a stronger plasticizing 
effect will exhibit on the same polymer. Even though the solid-state plasticization 
effect of indomethacin on Eudragit RL PO was weak, this study demonstrated that 
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indomethacin was miscible with Eudragit RL PO and a solid solution of 
indomethacin was formed during the extrusion process.   
The glass transition temperature of Eudragit RL PO was 62.88°C, and for 
IDM it was 47.77°C as determined by DSC.  After determining the Tg of the pure 
materials of IDM and Eudragit RL PO, the Tg of the mixture of Eudragit RL PO 
and IDM can be predicted by using the following Gordon-Taylor equation (70).   
Tg, mixture = [(m1Tg1) + (Km2Tg2)]/[m1 + (Km2)]        (1) 
Tg, mixture, Tg1, and Tg2 are the glass transition temperatures of the mixture, 
component 1 and component 2.  m1 and m2 are the weight percentage of component 1 
and component 2, respectively.  K can be calculated from the equation (2). 
K ≈ ρ1Tg1/ρ2Tg2      (2)  
ρ1, and ρ2 are the densities of component 1 and component 2.  By comparing the 
determined values with the predicted values as shown in Figure 4.5.2, we can see the 
determined values fit the Gordon-Taylor equation very well. 
The Tg was decreased with an increase of IDM, as described by the Gordon-
Taylor equation, demonstrating the solid-state plasticization effect of this model drug. 
IDM was also miscible with this acrylic polymer.   
 
4.5.3. Plasticization effect of Pluronic F68 on Eudragit RL PO 
Pluronic F68 was sieved through a 30 mesh screen before blending with 
Eudragit RL PO at different ratios.  The DSC scanning rate was 10 °C/min over a 
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temperature range of –20 to 150°C.  As the melting peak of Pluronic F68 was 
observed both in the first run and in the second run of all the samples, and the melting 
points of Pluronic F68 in these mixtures did not decrease significantly as seen in 
Table 4.5.3, this demonstrated that there was no plasticization effect of Pluronic F68 
on the Eudragit RL PO. 
 
4.5.4. Thermal stability 
 The thermal stability of indomethacin, Eudragit RL PO, Eudragit RD 100, 
Eudragit S 100, Eudragit L 100, and Pluronic F68 was investigated at the thermal 
processing temperature, 140°C.  Table 4.5.4 illustrates the weight percentage of these 
materials remaining after being kept at 140°C for 10 minutes.  The loss of mass of 
these materials at 140ºC for 10 minutes was less than 1%, indicating that 
indomethacin and the other excipients had good thermal stability.  The chemical 
stability of IDM was verified by HPLC (section 3.6).  In a previous study with 
another acrylic polymer, Eudragit RS PO was shown to be thermally stable at 120ºC 
for more than an hour (144).   
 
4.5.5. Adsorption of indomethacin on the acrylic polymers 
 The adsorption of IDM onto Eudragit RL 100 has been reported to prevent 
the drug from being completely released during a dissolution study (61). The 
adsorption of IDM in the pH 6.8 phosphate buffer solutions on the acrylic polymers, 
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including either the Eudragit RD 100, or Eudragit RD 100 with 10% Eudragit S 
100 or with 10% Eudragit L 100, is seen in Figure 4.5.3.   IDM had a strong binding 
with Eudragit RD 100 due to the existence of the quaternary ammonium groups in 
the acrylic polymer. When 10% of Eudragit S 100 was blended with Eudragit RD 
100, this interaction was weaker than with Eudragit RD 100 alone. This effect is 
contributed to the anionic functional groups in Eudragit S 100 and a lower amount 
of Eudragit RD 100 presence in the powder blend. When there were higher amounts 
of the anionic functional groups contained in the Eudragit L 100, even lower IDM 
and polymer binding was observed as seen in Figure 4.5.3.  
 
4.5.6. Chemical stability of IDM in the formulation 
For methyl methacrylate copolymers, previous research has shown that 
scission of polymer chains at elevated temperatures (300°C) results in a monomeric 
product (126). The depolymerization of poly(methl methacrylate) is a free-radical 
process that is initiated from the ends of the chain. Each initiated chain unzips rapidly 
to yield monomer formation. Thus, at any instant the system contains only unreacted 
polymer and monomer (127). The chemical stability of Eudragit RS PO is well 
documented (73). Therefore, only the chemical stability of IDM in the formulations 
following hot-melt extrusion was determined and the results are shown in Table 4.5.5. 
A HPLC method was used to evaluate the chemical stability of indomethacin.  By 
using the stability-indicating RP-HPLC, no additional peaks were detected.  Results 
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of this study demonstrated that indomethacin was chemically stable subject to thermal 
and pressure stress for only a few minutes (4). Other researches have demonstrated 
that indomethacin was quite stable in the molten   state (145). It was reported that 
only 1% of crystalline indomethacin was decomposed at 145°C after 48 hours. 
Amorphous indomethacin was less stable than its crystalline form, but it still needed 
several hours to begin to degrade (145). The chemical stability of IDM was reported 
in PVP/IDM (1:1) and PVP/IDM (4:1) systems processed at 170°C, and less than 1% 
of the active drug was chemically degraded (77).  
 
4.5.7. Drug release from hot-melt extrudates 
4.5.7.1. Influence of Pluronic F68 level and tablet processing on drug release 
 A powder blend containing 30% IDM, 66% Eudragit RD 100, and 4%TEC 
was processed by hot-melt extrusion.  The extradates were ground into granules in the 
particle size of 20-40 mesh and the drug release properties were determined.  It was 
found that only 36% of the drug was released after 12 hours in pH 6.8 using the USP 
24 paddle method.  A binding interaction between the acidic functional group in the 
drug and the quaternary amine group in the Eudragit RD would account for the low 
level of drug release. A non-ionic surfactant, Pluronic F68, a polyoxyethylene-
polyoxypropylene copolymer with a melting point of 56.2°C, was incorporated into 
the formulation to replace an equivalent amount of Eudragit RD 100.  As shown in 
Figure 4, an increase in drug release was observed with the increase in the Pluronic 
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F68 level in the granules.  This effect was contributed to the lower interfacial tension 
between the drug and the dissolution medium increasing the wettability of the drug in 
the formulation.  The drug release data showed a better fit with the Higuchi equation 
than with the first order drug release equation by comparing the linear regression 
coefficients.  The drug release rate constants were calculated and the drug release 
mechanism was shown to be a diffusion-controlled process.  The drug release rate 
constant increased from 10.24% h-1/2, to 15.32% h-1/2, and to 20.18% h-1/2 when the 
Pluronic F68 level increased from 0%, 5%, to 10%, respectively, in the hot-melt 
extrudates. The increase of nifedipine release from multiple-layer pellets containing 
Pluronic F68 was reported by several researchers (146).  
 The dissolution of the hot-melt extrudates containing different levels of 
Pluronic F68 with a particle size in the range of 40-60 mesh was also conducted, 
with the results reported in Figure 4.5.5.  Comparing Figure 4.5.4 and Figure 4.5.5, 
we see that the drug release rate was increased compared with the same formulation 
having a particle size in the range of 20-40 mesh.  From the Noyes-Whitney equation, 
drug dissolution rate is proportional to the surface area available for dissolution.  A 
decrease in the particle size of the extrudate increased the surface area exposed to 
dissolution, resulting in an increased drug release rate, as shown in Figure 4.5.5. 
Formulation of the granules of the solid solutions containing a poorly water-
soluble drug prepared by the hot-melt extrusion is of practical significance.  In this 
study, tablets containing the 50% of the granules of the solid solutions and 45% of 
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Avicel PH-101 were compressed.  To minimize the influence of the tablet 
formulation and the tableting processing on the drug release from the tablets, 5% L-
HPC (LH-21), a super disintegrant, was added to the formulation to ensure a fast 
disintegration of the compressed tablets.  At the compression force of 400 Kg, the 
compressed tablets had a hardness of 15Kg.  The drug release profiles from these 
tablets are seen in Figure 4.5.6.  Comparing the drug release from the tablets with the 
hot-melt extruded granules formed the tablets by calculating the similarity factor f2 
values, the f2 values were greater than 50 for the three formulations, suggesting that 
both the tablet formulation and the tabletting compression process did not 
significantly influence the drug release rate from the hot-melt extruded solid solution 
granules.   
 
4.5.7.2. Influence of Eudragit L100 and Eudragit S100 level on drug release 
 The dissolution profiles in both Figure 4.5.4 and Figure 4.5.5 demonstrate that 
a tailing effect is present with the extrudates containing the IDM.  After 12 hours, 
there was still more than 20% drug remaining in the granules to be slowly diffused 
from the polymer.  An approach to solving this problem was to include an enteric 
polymer in the formulation.  Eudragit L 100 or Eudragit S 100 were incorporated 
into the powder blend.  Drug release profiles from granules containing different levels 
of Eudragit L 100 in the formulation are seen in Figure 4.5.7.  With an increase in 
the amount of Eudragit L 100 added, the drug release rate increased. The Eudragit 
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L 100 is an anionic copolymer based on methacrylic acid and methyl methacrylate 
with a carboxylic acid functional group.  This polymer exhibits higher permeability at 
higher pH than Eudragit RD 100.  In addition, the incorporation of Eudragit L 100 
in the formulation decreased the binding of IDM with the Eudragit RD 100. These 
two factors contributed to the increased drug release rate of the polymeric systems 
containing of Eudragit L 100. 
The ratio of the free carboxyl groups to the ester groups is approximately 1:1 
in Eudragit L 100 and about 1:2 in Eudragit S 100.  Therefore, Eudragit S 100 has 
a lower permeability than Eudragit L 100.  Drug release profiles from granules 
containing different levels of Eudragit S 100 in the formulation are seen in Figure 
4.5.8.  The addition of Eudragit S 100 in the formulation did not enhance the drug 
release rate significantly.  The dissolution profiles comparison was carried out using a 
model independent method (56).  By calculating the similarity factor f2 values, it can 
be observed that the f2 values between the top two lines and the bottom two lines were 
greater than 50, which means that these dissolution profiles can be considered similar.  
Eudragit S 100 did not increase the drug release rate as high as Eudragit L 100 
since the release of the drug with a low solubility is primarily controlled by the 
relative magnitude of the rate of swelling/erosion of the polymer (147).   
 
4.5.7.3. Influence of TEC level on drug release 
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Pharmaceutical polymers used in thermal processing such as film coating, hot-
melt granulation, and hot-melt extrusion typically require a plasticizer in order to 
reduce the glass transition temperature of the polymer and to facilitate the thermal 
processing.  The addition of a plasticizer will usually decrease the drug release rate 
from polymeric coated systems since the plasticizer will increase the coalescence of 
the polymeric particles.  In a previous study it was reported that for hot-melt 
extrudated systems containing a highly water-soluble drug, chlorpheniramine 
maleate, the drug release rate increased with an increase in the plasticizer level (123).  
In this study, the drug release profiles from the hot-melt extrudates containing a 
poorly water-soluble drug, IDM, are shown in Figure 4.5.9.  The dissolution profiles 
comparison was carried out using the method mentioned above.  The f2 values were 
greater than 50, which means that these dissolution profiles can be considered similar.  
The addition of TEC in the hot-melt extrudate formulation containing a poorly water-
soluble drug did not influence the drug release, in the hot-melt extrusion process even 
though TEC had an effect on the formation of the structure of the drug delivery 
systems which governed the drug release from the polymeric delivery systems.  For 
the poorly water-soluble drug, the drug release is also controlled by the drug 
solubility. Kim reported that when a high drug loading is maintained for poorly 
water-soluble drugs, the addition of a water-soluble excipient to a matrix does not 
influence the release kinetics (147). Carli et al demonstrated that drug release from 
the Eudragit RS or Eudragit RL system was not influenced by porosity, whereas 
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the drug release rate was controlled by intraparticle diffusion (148). Lovrecich, et al 
revealed that for the indomethacin and Eudragit RS PO system, the diffusion 
coefficient of indomethacin through the polymer did not change with aging, although 
the polymer underwent local rearrangement. The driving force for water uptake was 
the presence of ionic groups. This proves that the physical parameters (free volume, 
short range order) of glassy polymers do not influence the diffusion (110).  
 
4.5.7.4. Influence of pH on drug release from granules 
 The profiles in Figure 4.5.12 demonstrate the effect of pH on drug release 
from the hot-melt extrudated granules.  Since the solubility of indomethacin was 
dependent on the pH of the media, the drug release rate increased with an increase in 
pH of the media. The pKa value of indomethacin is 4.5 (149).  The drug has a lower 
solubility at lower pH and a higher solubility at higher pH. 
 The drug release profiles in Figure 4.5.11 show 10% of the Eudragit L100 
incorporated in the formulation.  The drug release rate increased compared to the drug 
release at the same pH values shown in Figure 4.5.10, which could be contributed to 
the higher permeability of Eudragit L100 compared to Eudragit RD 100 in the 
corresponding pH media.   
 The drug release profiles in Figure 4.5.12 show 10% of the Eudragit S100 
incorporated in the formulation.  The drug release rate also increased as compared 
with the drug release at the same pH values in Figure 4.5.10, but it increased to a 
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lesser extent as compared with Eudragit L100.  As described earlier, this is due to 
the lower permeability of the Eudragit S 100 than that of Eudragit L100 in the 
corresponding pH media.   
The drug release from the delivery systems in the different pH media can be 
determined conveniently by using the Bio-Dis apparatus. The Bio-Dis apparatus  
(method 3) eliminates manual and tedious work in changing dissolution media, 
providing an advantage when dissolution testing is performed in a pH step gradient 
(150, 151).  Figure 4.5.13 shows that the drug release rate increased with both pH and 
the incorporation of the Eudragit L100 or the Eudragit S100 for reasons described 
above.   
 
4.5.8. Microstructures and crystallinity of the hot-melt extrudates 
The scanning electron micrographs in Figure 4.5.14 show the microstructure 
of the hot-melt extrudates of IDM.  A continuous single phase was observed for both 
formulations, demonstrating that IDM was homogenously dispersed in the hot-melt 
extrudates.  In addition to the DSC results, the photographs in Figure 4.5.14 also 
demonstrate that IDM was miscible with the acrylic polymer in the molten state.  A 
brittle structure is seen for the formulation with no TEC, in Figure 4.5.14 (A).  In 
comparison, when 4% TEC was added to the formulation, a smoother structure with 
lesser brittle character is seen in Figure 4.5.14 (B).   
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Pluronic F68 and indomethacin are crystalline materials as shown by the X-
ray profiles with peaks in Figure 4.5.15.  Eudragit RD 100, which is composed of a 
mixture of sodium CMC and Eudragit RL 100, exhibited no evidence of crystalline 
peaks, showing it to be an amorphous polymer.  The physical blend containing 30% 
IDM exhibited some peaks.  The X-ray profile for the extrudate showed the absence 
of peaks, indicating that IDM was in an amorphous form and a solid solution was 
formed following the hot-melt extrusion process.  A related study also revealed that 
solid dispersions of indomethacin and Eudragit RS prepared by the solvent method 
resulted in the formation of an amorphous form of IDM when present at 
concentration as high as 30% (w/w) (61).  
Several pharmaceutical processes, including spray drying, lyophilization, and 
milling have been shown to transform a crystalline drug transform into different 
polymorphous structures. An amorphous form of drug is formed first due to a lower 
interfacial energy of the metastable nucleus against the amorphous matrix than that of 
the more stable nucleus against this matrix as explained by Ostwald (19, 152). The 
transformation of crystalline IDM into amorphous form as a result of thermal 
processing enhanced the solubility of the model drug, thus decreasing the influence of 
solubility of the poorly water-soluble drug on the drug release and increasing the 
influence of the delivery system.  In addition, the formation of a molecularly 
distributed drug in the system also eliminates the influence of drug particle size on 
drug release, which is a major concern for poorly water-soluble drugs.   
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When 10% Eudragit S 100 replaced the same amount of Eudragit RD 100 in the 
hot-melt extrudate formulations as seen in Figure 4.5.16, the peak intensity was 
higher as compared with the formulation without Eudragit S 100 (the top line in 
Figure 4.5.15).  This is because IDM was immiscible with Eudragit S 100 in the 
molten state.  When more than 10% of Eudragit S 100 was added to the formulation 
to replace the same amount of Eudragit RD 100, an increase in crystallinity of IDM 
was found following the thermal processing. 
 
 
In conclusion, IDM decreased the glass transition temperature of the 
Eudragit RL PO as determined by DSC demonstrating that IDM exhibited a solid-
state plasticization effect on the polymer and IDM was miscible with this polymer in 
the molten state.  An amorphous form of IDM was converted from the crystalline 
form and a solid solution of IDM was formed following the hot-melt extrusion 
process of the formulation containing Eudragit RD 100 as demonstrated by the X-
ray diffraction, the DSC and the SEM profiles.  Eudragit RD 100/L 100/S 100 were 
thermally stable at 140°C for 10 minutes as shown by TGA.  IDM was chemically 
stable in the formulations following hot-melt extrusion as determined by a USP 
stability indicating RP-HPLC assay.  The drug and polymer adsorption study 
demonstrated that IDM had a strong binding with the Eudragit RD 100 resulting in 
an incomplete drug release from the extrudated granules.  When 10% of the 
Eudragit L 100 or Eudragit S 100 was blended with Eudragit RD 100, a weaker 
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interaction was observed due to the presence of the anionic functional group in the 
Eudragit L 100 or Eudragit S 100.  The drug release rate from the hot-melt 
extrudates solid solutions increased with a decrease in granule particle size, with the 
addition of the Pluronic F68, Eudragit L 100 or Eudragit S 100, and also with an 
increase in the pH of the dissolution media due to the increased wetability and 
solubility of the drug, increased permeability of the polymer, or decreased drug and 
polymer interaction. The incorporation of TEC, the further formulation and 
processing of the hot-melt extrudated granules with Avicel PH-101 and L-HPC into 
tablets showed no significant influence on drug release from the granules.  SEM 
photographs showed that IDM was homogeneously distributed in the hot-melt 
extrudates and that the addition of TEC decreased the brittle character of the 
extrudate.   
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CHAPTER FIVE: SUMMARY AND CONCLUSIONS 
 
The influence of in situ plasticization of chlorpheniramine maleate (CPM) on 
Eudragit RS PO from hot-melt extruded matrix tablets, and from compressed 
granules prepared by thermal processing was investigated. CPM was studied as both a 
model drug substance and as a solid-state plasticizer for the acrylic polymer.  Triethyl 
citrate (TEC) was incorporated into the polymer blend as a liquid plasticizer for the 
polymer. The influence of TEC and CPM concentration on the dissolution properties 
of CPM tablets was investigated. The glass transition temperature (Tg) of the samples 
was determined by modulated differential scanning calorimetry. The morphologies of 
the granules formed by hot-melt extrusion and hot-melt granulation processes were 
investigated by scanning electron microscopy. The addition of 12% TEC to the 
polymer reduced the Tg by 32.5°C, while the reduction in the Tg for the same level of 
CPM was 16.4°C. The effect of TEC levels on drug release was dependent on the 
tablet preparation method. At high TEC levels, the release rate of CPM decreased in 
tablets prepared by direct compression and tablets made from compressed granules 
that had been prepared by high shear hot-melt granulation. However, the CPM release 
rate increased from hot-melt extruded tablets with increasing blends of plasticizer in 
the extruded tablets. An increase in the CPM content in the tablets resulted in an 
increase in the drug release rate. During high shear hot-melt granulation, the model 
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drug adhered to the polymer to form a porous discontinuous structure. Following hot-
melt extrusion, the drug was distributed at a molecular level in the continuous 
polymeric structure. The influence of both CPM and TEC levels on the drug release 
rate from these polymeric drug delivery systems was shown to be a function of 
whether the granules or tablets were formed by either hot-melt granulation or hot-
melt extrusion, as well as the plasticization effects of both TEC and CPM on the 
acrylic polymer. 
To determine the effects of thermal processing and post-processing thermal 
treatment on the release properties of chlorpheniramine maleate (CPM) from matrix 
tablets containing Eudragit RS PO and triethyl citrate (TEC), CPM tablets 
containing Eudragit RS PO with and without TEC were prepared by direct 
compression, high shear hot-melt granulation and hot-melt extrusion.  X-ray 
diffraction patterns showed that the CPM was distributed in Eudragit RS PO at the 
molecular level following hot-melt extrusion. The TGA profiles of CPM, Eudragit 
RS PO and TEC demonstrated that these materials were thermally stable during both 
the high shear hot-melt granulation and hot-melt extrusion processes. The tablets 
were subjected to post-processing thermal treatment by storing the tablets at 60°C in 
open containers for 24 hours. Tablets prepared by direct compression showed the 
highest drug release rate constant of 36.2%h-1/2. When 4% TEC was incorporated into 
the formulation, the drug release rate constant for the directly compressed tablets 
decreased to 32.4%h-1/2. After high shear hot-melt granulation and hot-melt extrusion 
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of the powder blend containing 4% TEC, the drug release rate constant decreased to 
30.8%h-1/2 and 13.8%h-1/2 for the respective processes. The drug release rate constants 
for all tablets decreased following post-processing thermal treatment. The reduction 
in release rate was due to an increase in the intermolecular binding and entanglement 
between drug molecules and polymer molecules that occurred during thermal 
processing. Post-processing thermal treatment of the hot-melt extrudates had a 
minimal effect on the drug release rate since the hot-melt extrusion process enhanced 
the drug and polymer entanglement to a greater extent.  
To investigate the influence of a lipophilic thermal lubricant on the processing 
conditions and properties of chlorpheniramine maleate (CPM) tablets prepared by 
hot-melt extrusion, CPM tablets containing Eudragit RS PO, triethyl citrate (TEC) 
and glyceryl monostearate (GMS) were prepared by hot-melt extrusion at 95°C (die). 
The thermal stability of CPM, Eudragit RS PO, TEC, and GMS were determined by 
thermogravimetric analysis (TGA). The influence of the concentration of thermal 
lubricant and plasticizer level on the thermal processing parameters was determined. 
The effect of the GMS level on the drug release properties of CPM hot-melt extruded 
tablets was investigated. Differential scanning calorimetry (DSC) was used to 
investigate the compatibility of the drug and the functional excipients. The 
morphologies of the extrudates were investigated by scanning electron microscopy 
(SEM). In addition, X-ray diffractometry was employed to study the crystallinity of 
CPM in the hot-melt extrudates. Thermal stability studies showed that CPM and the 
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excipient components of the extruded tablets were stable at the thermal processing 
temperature. The incorporation of TEC or GMS in the powder blend decreased the 
drive AMPS and the torque values in the hot-melt extrusion process. The glass 
transition for Eudragit RS PO and the melting behavior of GMS were determined 
with the powder mixture of GMS and Eudragit RS PO. The results demonstrated 
that these two materials were not miscible in the molten state. These results were in 
agreement with the findings from the SEM and X-ray diffraction studies. An increase 
in the thermal lubricant level in the Eudragit RS PO system resulted in an increase in 
the rate of drug release from the tablets. TEC and GMS facilitated the thermal 
processing to prepare CPM controlled-release matrix tablets containing an acrylic 
polymer by hot-melt extrusion. TEC lowered both the glass transition temperature 
and the melt viscosity of the acrylic polymer. The lipophilic lubricant only decreased 
the melt viscosity of the acrylic polymer and had no effect on the glass transition 
temperature.  
In the current study, the influence of plasticizer level on drug release was 
investigated for two thermal processes: hot-melt extrusion and film coating. Two 
highly water-soluble model drugs, diltiazem hydrochloride (DTZ) and 
chlorpheniramine maleate (CPM), and a poorly water-soluble drug, indomethacin 
(IDM) were selected in the hot-melt extruded formulations containing Eudragit RS 
PO or Eudragit RD 100 and TEC. In addition, pellets containing DTZ were film 
coated with Eudragit RS 30D and varying levels of TEC using a fluidized bed 
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coating unit. Both CPM and IDM exerted the plasticization effect on the acrylic 
polymers. No plasticizing effect of DTZ on Eudragit RS PO was observed from 
differential scanning calorimetry (DSC).  Thermogravimetric analysis (TGA) data 
showed the thermal stability of the DTZ, Eudragit RS PO and TEC under the hot-
melt extrusion temperature 140°C. Drug content determined by HPLC indicated the 
chemical stability of DTZ in the formulation following hot-melt extrusion. Drug 
release rates of both DTZ and CPM from hot-melt extrudates increased with an 
increase in the TEC level in the formulations, while DTZ release from the Eudragit 
RS 30D coated pellets decreased with an increase of TEC in the coating layer. This 
observation could be attributed to the fact that a continuous polymeric structure was 
formed following hot-melt extrusion regardless of the TEC level. However, for the 
film coated pellets coalescence of the polymer particles was enhanced with higher 
levels of TEC as revealed by SEM.  The addition of TEC (0% to 8%) in the hot-melt 
extrudate formulation containing IDM did not influence the drug release rate as the 
drug release rate was controlled by intraparticle diffusion for poorly water-soluble 
drugs.   
To investigate the physicochemical and drug release properties of controlled 
release hot-melt extrudates containing a poorly water-soluble drug, indomethacin 
(IDM). IDM tablets containing Eudragit RD 100, and triethyl citrate (TEC) were 
prepared by hot-melt extrusion using a Randcastle Microtruder RCP-0750 vertical 
single screw extruder.  The crystal habit and the particle size of IDM were determined 
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and the true density was determined using a helium pycnometer.  Differential 
scanning calorimetry (DSC) was employed to investigate the melting point of IDM 
and the plasticization effects of both IDM and Pluronic F68 on the acrylic polymer.  
Thermogravimetric analysis (TGA) was used to study the thermal stability of the 
these materials under the hot-melt processing conditions.  The chemical stability of 
IDM following thermal processing and the amount of drug release from the hot-melt 
extrudates during dissolution testing were determined by RP-HPLC.  Dissolution 
studies were conducted according to the USP 24 apparatus 2 method at 37°C and 100 
rpm in pH 6.8 phosphate buffer solution and also according to the USP 24 apparatus 3 
method at pH 1.2, 5.0, 6.8, and 7.4.  The influence of granule size, and the 
mechanism of Pluronic F68, Eudragit S 100, Eudragit L 100, TEC in the 
extrudate on drug release was investigated.  The microstructure of the hot-melt 
extrudates was examined by SEM.  X-ray diffractometry was used to investigate the 
crystallinity of the model drug following hot-melt extrusion.  IDM was found to be 
thermally stable at the hot-melt extrusion processing temperatures and displayed a 
plasticizing effect on the Eudragit RL PO as revealed by a decrease in the glass 
transition temperatures of the polymer.  The inclusion of the Pluronic F68, 
Eudragit L 100 or Eudragit S 100 in the powder blend prior to processing increased 
the rate of release of the IDM from the extrudates.  An increase in the media pH or a 
decrease in the granule particle size also increased the rate of release of IDM.  The 
inclusion of TEC up to 8% in the granule formulation or compressing the granules 
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with Avicel PH-101 and L-HPC in the tablets did not influence the drug release.  
IDM was transformed from the crystalline Form I into an amorphous form in the 
Eudragit RD 100 granules following hot-melt extrusion.  Controlled release tablets 
containing IDM and acrylic polymers were successfully prepared by hot-melt 
extrusion.  The thermal processing facilitated the formation of a solid solution with a 
continuous matrix structure that was shown to decrease drug diffusivity from the hot-
melt extrudates.   
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Table 1.3.1. Drug release mathematical models 
_____________________________________________________ 
Zero order  Qt = Q0 + Kt 
First order  ln Qt = ln Q0 + Kt 
Higuchi  Qt = Kt1/2 
Hixson-Crowell Q∞ 1/3 - Qt 1/3 = Kt 
Korsmeyer-Peppas Qt / Q∞ = Ktn 
Baker-Lonsdale (3/2)[1-(1-(Qt / Q∞ ))2/3] - (Qt / Q∞ ) = Kt  
_____________________________________________________ 
Qt is the amount of drug released after time t.  
Q∞ is the total amount of drug in the dosage form. 
t is the drug release time. 
K is a drug release constant. 
n is the release exponent, indicative of the mechanism of drug release. Zero-
order and anomalous release kinetics are represented by 0.89<n<1.0 and 






Table 3.2.1. Hot-melt extrusion processing temperatures at different zones for CPM, 
DTZ, and IDM. 
 
            Temperatures of Different Heating Zones 
______________________________________________________ 
 Drugs  Zone 1  Zone 2  Zone 3  Zone 4 (die) 
_____________________________________________________________________ 
CPM  90°C  105°C  110°C   115°C 
DTZ  90°C  120°C  135°C   140°C  















Table 3.2.2. Film coating conditions.   
 
Preheating temperature 35°C 
Preheating time 2 minutes 
Inlet temperature 35-40°C 
Outlet temperature 32-34°C 
Air pressure 1.5 Kg/cm2  
Spray rate 2.0g/min 














Table 3.2.3. Dissolution methods for CPM, TEC, DTZ, and IDM. 
 
 CPM and TEC DTZ IDM 
Method USP 24 basket USP 24 paddle USP 24 paddle 
Dissolution 
medium 
Distilled water, 500ml PH 7.2 PBS, 900ml PH 6.8 PBS, 900ml
Rotation speed 100rpm 50rpm 75rpm 
Temperature 37°C 37°C 37°C 
Determination 
method 
UV, 261nm (CPM) 
HPLC (TEC), 220nm 














Table 3.2.4. HPLC methods for CPM, DTZ, IDM, and TEC. 
 
































































Figure 4.1.1. Influence of triethyl citrate levels on the dissolution properties of 
Eudragit RS PO tablets containing chlorpheniramine maleate  (10%, w/w), prepared 
by direct compression of powder blend (DC) or high shear hot-melt granules (HMG). 
Compression force: 2000Kg. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (○): 0% triethyl citrate, DC; 
(□): 4% (w/w) triethyl citrate, DC; (∆): 7% (w/w) triethyl citrate, DC; (●): 0% triethyl 
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Figure 4.1.2. Influence of triethyl citrate levels on the dissolution properties of 
Eudragit RS PO hot-melt extruded tablets containing chlorpheniramine maleate  
(10%, w/w).  
Dissolution: USP 24 basket method, 100rpm, 500ml distilled water as the dissolution 
medium, 37°C (n=3). (●): 0% triethyl citrate; (■): 4% (w/w) triethyl citrate; (▲): 7% 



























Figure 4.1.3. Release of triethyl citrate from the hot-melt extruded Eudragit RS PO 
tablets containing chlorpheniramine maleate  (10%, w/w) with time. 
Dissolution: USP 24 basket method, 100rpm, 500ml distilled water as the dissolution 








































Figure 4.1.4. Influence of chlorpheniramine maleate  levels on the dissolution 
properties of hot-melt extruded chlorpheniramine maleate  tablets containing 
Eudragit RS PO and 4% (w/w) triethyl citrate.  
Dissolution: USP 24 basket method, 100rpm, 500ml distilled water as the dissolution 
medium, 37°C (n=3). (∆): 6% (w/w) chlorpheniramine maleate ; (□): 10% (w/w) 































Figure 4.1.5. Influence of chlorpheniramine maleate  levels on the dissolution 
properties of chlorpheniramine maleate  tablets containing Eudragit RS PO and 4% 
(w/w) triethyl citrate prepared with hot-melt extruded granules.  
Compression force: 2000Kg. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (∆): 6% (w/w) 
chlorpheniramine maleate ; (□): 10% (w/w) chlorpheniramine maleate ; (○): 14% 



























Figure 4.1.6. Influence of chlorpheniramine maleate  levels on the dissolution 
properties of chlorpheniramine maleate  tablets containing Eudragit RS PO and 4% 
(w/w) triethyl citrate prepared with high shear hot-melt granules.  
Compression force: 2000Kg. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (∆): 6% (w/w) 
chlorpheniramine maleate; (□): 10% (w/w) chlorpheniramine maleate; (○): 14% 
























Figure 4.1.7. Glass transition temperature of Eudragit RS PO as a function of 
chlorpheniramine maleate  and triethyl citrate level, determined by MDSC (n=3).  
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Figure 4.1.8. SEM photographs of processed CPM formulations.  
(A), Physical mixture of chlorpheniramine maleate    and Eudragit RS PO; (B), 
Physical mixture of chlorpheniramine maleate, Eudragit RS PO, and triethyl citrate;  
(C, D), High shear hot-melt granules containing triethyl citrate plasticized Eudragit 
RS PO and chlorpheniramine maleate at two magnifications; (E, F), Hot-melt 
extruded granules containing triethyl citrate plasticized Eudragit RS PO and 
chlorpheniramine maleate  at two magnifications.   
( B ) 
( C ) ( D ) 
( E ) ( F ) 







Figure 4.2.1. Influence of post-processing thermal treatment (at 60°C) on the 
dissolution profiles of Eudragit RS PO tablets containing CPM (10%), prepared by 
direct compression.  
Compression force: 2000Kg. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (○): Before treatment; (●): 























Figure 4.2.2. Influence of post-processing thermal treatment (at 60°C) on the 
dissolution profiles of Eudragit RS PO tablets containing CPM (10%) and TEC (4%), 
prepared by direct compression.  
Compression force: 2000Kg. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (○): Before treatment; (●): 1.0 
























Figure 4.2.3. Influence of post-processing thermal treatment (at 60°C) on the 
dissolution profiles of Eudragit RS PO tablets containing CPM (10%) and TEC (4%), 
prepared by high shear mixer hot-melt granulation.  
Processing temperatures: 60°C. Compression force: 2000Kg. Dissolution: USP 24 
basket method, 100rpm, 500ml distilled water as the dissolution medium, 37°C (n=3). 






















Figure 4.2.4. Influence of post-processing thermal treatment (at 60°C) on the 
dissolution profiles of hot-melt extruded tablets containing Eudragit RS PO, CPM 
(10%) and TEC (4%).  
Processing temperatures: Zone 1, 2, 3, and 4 (die): 90°C, 105°C, 110°C, and 115°C 
respectively. Screw rate: 20 rpm. Dissolution: USP 24 basket method, 100rpm, 500ml 
distilled water as the dissolution medium, 37°C (n=3). (○): Before treatment; (●): 1.0 











































Figure 4.2.5. Thermal stability of CPM, Eudragit RS PO and TEC was determined 












Figure 4.2.6. Dynamic thermal stability of CPM, Eudragit RS PO and TEC were 
determined using thermogravimetry analysis (TGA) with temperatures held at 120°C 























Figure 4.2.7. Dynamic thermal stability of CPM, Eudragit RS PO and TEC were 
determined using thermogravimetry analysis (TGA) with temperatures held at 160°C 









Figure 4.2.8. X-ray diffraction patterns of CPM, Eudragit RS PO, and three 
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Figure 4.2.9. X-ray diffraction patterns of hot-melt extruded granules of Eudragit RS 
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Table 4.3.1. Influence of thermal processing temperature on the processing 
parameters for Eudragit RS PO. 
____________________________________________________________ 
   Heating Zones        Processing Temperature at Different Zones  
        Zone 1  120°C  115°C  110°C  110°C 
        Zone 2  160°C  150°C  140°C  130°C 
        Zone 3  180°C  160°C  150°C  140°C 
        Zone 4  190°C  170°C  160°C  150°C          
  Drive AMPS  2.04±0.14 2.74±0.30 3.20±0.30       3.66±0.16 























Table 4.3.2. Influence of TEC on the hot-melt processing parameters for Eudragit 
RS PO. 
____________________________________________________________ 
Heating        Processing Materials     
Zones  Eudragit  Eudragit   Eudragit  
  RS PO    RS PO+4%TEC RS PO+8%TEC 
Zone 1  110°C   110°C   110°C  
Zone 2  130°C   130°C   130°C  
Zone 3  140°C   140°C   140°C  
Zone 4  150°C   150°C   150°C   
Drive AMPS 3.66±0.16  1.92± 0.18  1.14±0.06  















Table 4.3.3. Influence of GMS on the hot-melt processing parameters for Eudragit 
RS PO. 
____________________________________________________________ 
Heating        Processing Materials     
Zones  Eudragit RS  Eudragit RS  Eudragit RS  Eudragit RS 
                          PO  PO+10%GMS PO+20%GMS PO+30%GMS  
Zone 1  110°C  110°C  110°C  110°C  
Zone 2  130°C  130°C  130°C  130°C  
Zone 3  140°C  140°C  140°C  140°C  
Zone 4  150°C  150°C  150°C  150°C   
Drive AMPS  3.66±0.16  1.39±0.02 0.90±0.01 0.86±0.01    






















Figure 4.3.1. Thermal stability of CPM, Eudragit RS PO, GMS, and TEC isothermal 
































Figure 4.3.2. Influence of TEC on the reduction of hot-melt viscosity of Eudragit RS 
PO. 
(Temperatures for zone 1, zone 2, and zone 3: 140°C, 130°C, and 110°C. Screw 
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Figure 4.3.3. Influence of GMS on the reduction of hot-melt viscosity of Eudragit 
RS PO.  
(Temperatures for zone 1, zone 2, and zone 3: 140°C, 130°C, and 110°C. Screw 
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Figure 4.3.5. SEM photographs of the hot-melt extrudates containing 5% GMS.  



















Figure 4.3.6. Influence of GMS on the drug release from hot-melt extruded tablets.  
Dissolution: USP 24 basket method, 100rpm, 500ml distilled water as the dissolution 
medium, 37°C (n=3). (○): 0% GMS; (●): 5% GMS; (∆): 10% GMS; (▲): 15% GMS; 








































Figure 4.3.7. X-ray diffraction patterns of hot-melt extruded CPM granules 
















1. GMS,  2. CPM 
3. CPM (14%), Eudragit RS PO, and     
GMS (10%) physical mixture 
4. CPM (14%), Eudragit RS PO, and 
GMS (10%) hot-melt extrudate 












Table 4.4.3. DTZ content in the formulation prior to and following hot-melt 
extrusion. 
_____________________________________________________________________              
Formulations                  DTZ content                      DTZ content 
  before hot-melt extrusion     after hot-melt extrusion 
_____________________________________________________________________ 
DTZ (30%), Eudragit RS PO 99.96±2.21          97.91±1.32 
(66%), TEC (4%) 
 
DTZ (30%), Eudragit RS PO 100.4±0.21          98.93±0.56 
























Figure 4.4.1. Thermal stability of TEC, DTZ, and Eudragit RS PO determined from 


































Figure 4.4.2. Glass Transition temperatures of the mixture of Eudragit RS PO and 
































Figure 4.4.3. Influence of TEC levels on the dissolution properties of Eudragit RS 
PO hot-melt extruded tablets containing CPM (10%).  
Dissolution: USP 24 basket method, 100rpm, 500ml distilled water as the dissolution 





























Figure 4.4.4. Influence of TEC Level on the dissolution rate of DTZ from hot-melt 
extruded tablets containing DTZ 30%, Eudragit RS PO+TEC=70%.  
Dissolution: USP24 paddle method, 50rpm, pH 7.2 PBS, 37°C (n=3). (●): 0% TEC; 







































Figure 4.4.5. Influence of TEC level in the Eudragit RS 30D coating layer on the 
dissolution rate of DTZ from coated pellets with a 15% weight gain.  
Dissolution: USP24 paddle method, 50rpm, pH 7.2 PBS, 37°C (n=3). (●): 10% TEC; 

























































Fgure 4.4.6. Influence of TEC on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100 and 5% Pluronic® 
F68.  
Dissolution: USP24 paddle method, 50rpm, pH 7.2 PBS, 37°C (n=3). (●): 0% TEC; 




































Figure 4.4.7. SEM photograph of hot-melt extrudates containing 30% DTZ, 66% 







































     (C) 20% TEC 
Figure 4.4.8. SEM photographs of Eudragit RS 30D coated DTZ beads containing 
different level of TEC in the coating layer with 15% weight gain based on solid 
polymer.  


































Physical mixture of DTZ(30%), Eudragit RS PO(66%), and TEC(4%)




Table 4.5.1. Particle size of the model drug and the acrylic polymers determined by 
ZetaPlus Zeta potential analyzer (n=3). 
 
Materials  Indomethacin  Eudragit RL PO Eudragit RD 100 
Effective Diameter 13.94    34.66   39.73  
(µm)  13.29   41.90   43.25  
   14.70   46.32   46.35  
Average Effective  13.98   40.96   43.11 
Diameter (µm) 

































Table 4.5.2. True density of indomethacin and acrylic polymers determined by 
AccuPyc 1330 pycnometer (n=3). 
Materials  Indomethacin  Eudragit RL PO Eudragit RD 100 
Density  13760    1.1901   1.2148 
(g/cm3)  1.3759   1.1881   1.2074 
   1.3756   1.1880   1.2061 
Average    1.3756   1.1887   1.2094 
Density (g/cm3)  



















Table 4.5.3.  Melting points of Pluronic F68 in the mixture of Eudragit RL PO. 
% of Pluronic F68  First run melting point°C Second run melting 
point°C 
10%    54.26    55.22 
 
20%     53.57    55.22 
 
30%     54.26    55.70 
 
40%     54.74    56.17 
 
50%     53.78    54.98 
 















Table 4.5.4.  Thermal stability of indomethacin and other excipients (Isothermal at 
140°C for 10 minutes determined by TGA). 
 
_____________________________________________________________________ 
                Materials 
_________________________________________________________ 
  IDM      Pluronic  Eudragit    Eudragit     Eudragit   Eudragit 
                                            F68  RD 100      RL PO         S 100         L 100 
_____________________________________________________________________
Remaining  99.8           99.9           99.3           99.8           99.8           99.8 




















Table 4.5.5.  Chemical stability of indomethacin in the formulations containing 
acrylic polymers following hot-melt extrusion determined by HPLC. 
_____________________________________________________________________                     
Formulations                             IDM content          IDM content 
             before HME            after HME 
_____________________________________________________________________ 
IDM (30%), Eudragit RD 100 (61%),  97.09±0.88          97.69±0.95 
Pluronic F68 (5%),  TEC (4%) 
 
IDM (30%), Eudragit RD 100 (51%),  101.9±1.01              99.83±0.19 
Eudragit L 100 (10%), Pluronic F68 
(5%),  TEC (4%) 
 
IDM (30%), Eudragit RD 100 (51%),  103.5±1.57          103.3±0.24 
Eudragit S 100 (10%), Pluronic F68 
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Figure 4.5.2.  Glass transition temperatures of mixtures of Eudragit RL PO and 
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Figure 4.5.3. Adsorption of IDM in the pH 6.8 phosphate buffer solutions on the 









































Figure 4.5.4.  Influence of Pluronic® F68 on indomethacin release from hot-melt 
extrudated granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100, 
Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●): 0% 







































Figure 4.5.5.  Influence of Pluronic® F68 on indomethacin release from hot-melt 
extrudated granules (40-60 mesh) containing 30% IDM, Eudragit® RD 100, 
Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●): 0% 











Tablet formulation: 250mg granules, 225mg of Avicel PH101 and 25mg of L-
HPC LH-21. Compression force: 400 kg






















Figure 4.5.6.  Influence of tableting on indomethacin release from tablets made with 
the granules (40-60 Mesh) containing 30% IDM, Eudragit® RD 100, Pluronic® F68 
and 4% TEC prepared by hot-melt extrusion.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●): 0% 














Dissolution: USP 24 paddle method, 75rpm, 900ml 






















Figure 4.5.7.  Influence of Eudragit® L 100 on indomethacin release from hot-melt 
extrudated granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100, 5% 
Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●): 0% 













Dissolution: USP 24 paddle method, 75rpm, 900ml 

















20% Eudragit S 100
10% Eudragit S 100
0% Eudragit S 100
 
 
Figure 4.5.8.  Influence of Eudragit® S 100 on indomethacin release from hot-melt 
extrudated granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100, 
Eudragit® S 100, 5% Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●):0% 

































Figure 4.5.9.  Influence of TEC on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100 and 5% Pluronic® 
F68.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●): 0% TEC; 




































Figure 4.5.10. Influence of pH on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, 61% Eudragit® RD 100, 5% Pluronic® 
F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, pH 6.8 PBS, 37°C (n=3).  (●):pH 1.2; 






































Figure 4.5.11.  Influence of pH on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, 51% Eudragit® RD 100, 10% 
Eudragit® L 100, 5% Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, 37°C (n=3).  (●): pH 1.2; (▲): pH 5.0; 




































Figure 4.5.12.  Influence of pH on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, 51% Eudragit® RD 100, 10% 
Eudragit® S 100, 5% Pluronic® F68 and 4% TEC.   
Dissolution: USP24 paddle method, 75rpm, 37°C (n=3).  (●): pH 1.2; (▲): pH 5.0; 






























10% Eudragit L 100
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Figure 4.5.13.  Influence of pH on indomethacin release from hot-melt extrudated 
granules (20-40 mesh) containing 30% IDM, Eudragit® RD 100, 5% Pluronic® F68 
and 4% TEC.   
Dissolution: USP24 method 3, 20 dip/min, 250 ml, 37°C (n=3).  (●): 0% Eudragit® S 






































Figure 4.5.14.  SEM photographs of hot-melt extrudates.   
(A) 30% IDM, 65% Eudragit® RD 100, 5% Pluronic F68, and 0% TEC; (B) 

















Physical mixture of IDM(30%), Eudragit RD 100(61%), Pluronic F68(5%), TEC(4%)
P
Hot-melt extrudate of IDM(30%), Eudragit RD 100(61%), Pluronic F68(5%), TEC(4%)
 
 
Figure 4.5.15.  X-Ray diffraction patterns of IDM, Eudragit® RD 100, Pluronic® 























              Physical mixture of IDM (30%), Eudragit RD 100(51%), S-100 (10%), Pluronic F68(5%), and TEC (4%)
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              Hot-melt extrudates of IDM (30%), Eudragit RD 100(51%), S-100 (10%), Pluronic F68(5%), and TEC (4%)
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